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SUMMARY 
Our understanding of the malleability of cell identity has radically changed in the last half 
century.  It was thought that once a cell terminally differentiated into its end state, that 
cell’s identity was set. Gurdon, challenged this idea in 1958, with the first successful 
generation of a cloned animal from a somatic cell nucleus by utilizing somatic cell 
nuclear transfer (SCNT), thus proving that the totipotent potential of a mature somatic 
cell could be reactivated (Gurdon et al. 1958). Almost 50 years later, Takahashi and 
Yamanaka (2006) also proved the pluripotent stem cell state attainable from a terminally 
differentiated fibroblast, by a radically new method. A better understanding of the 
transcriptional control of the pluripotent state allowed for directed reprogramming of 
somatic cells by selective overexpression of nuclear transcription factors specifying for 
the pluripotent state, hence resulting in induced pluripotent stem cells (iPS; Takahashi 
and Yamanaka 2006). The stem cell research field has embraced this idea with gusto as 
exemplified by the flood of published reprogramming articles in the years that followed 
(Davis et al. 1987; Idea et al. 2010; Takahashi and Yamanaka 2006; Vierbuchen et al. 
2010).   
These breakthroughs in the understanding and manipulation of cell identity, besides being 
an exciting research tool to investigate mammalian development, have therapeutic 
potential, in the form of personalized cell therapy or “disease modeling”. Current organ 
transplant protocols often require a life-long treatment with immunosuppressive drugs 
due to the limited availability of matched tissues between non-related individuals. The 
ability to generate iPS may circumvent these problems as they may be differentiated into 
the required tissues using cells already genetically matched to the patient. Existing 
disease models are necessarily studied in non-human species, or limited by access to 
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primary disease tissues. These studies would benefit greatly from the ability to 
recapitulate the disease in vitro, through differentiation of the afflicted tissues from the 
patient’s own skin cells, thus providing ample samples by which to assess treatments in a 
patient-specific manner.  
Specifically within the realm of hematopoietic diseases, such as leukemia, therapies rely 
on the harvest of primary hematopoietic stem cells (HSC) from the patient or matched 
donor, and limited expansion in vitro, before transplantation back into the patient.  
However, these therapies fall far short of the optimal 107 CD34+ HSC cells/kg 
recommended for successful treatment in adults (Lickliter et al. 2000; Sharp et al. 2000). 
As ex vivo methods of primary HSC expansion are inadequate, directed differentiation of 
embryonic stem cells (ESC) into the adult hematopoietic system has been shown in both 
mouse (Kitajima et al. 2003; Keller et al. 2002) and human (D. S. Kaufman et al. 2001; 
Zambidis et al. 2005; Chang et al. 2006; Ma et al. 2008). Despite these successes, 
evidence of long-term engraftment by ESC-derived HSCs is sparse (as reviewed by Olsen 
et al. 2006; Huber 2010).  
Thus in an effort to bypass some of the current limitation in ESC differentiation, we 
utilized advancements in the understanding of cellular plasticity, as well as the vast 
amounts of information accrued about the hematopoietic field, to reprogram murine 
fibroblasts into hematopoietic progenitors. We achieved this goal by overexpression of 
select hematopoietic-specific nuclear regulators combined with appropriate 
hematopoietic cellular co-culture conditions to successfully produce induced 
hematopoietic cells in culture. The use of both a hematopoietic supportive stromal cell 
line and a combination of cytokines well known to maintain HSCs in culture aided 
generation of viable suspension cells showing hematopoietic identity through cell surface 
! ! !!xiii!
marker staining, and progenitor potential through in vitro differentiation assays. In vivo 
assessment of these hematopoietic-reprogrammed cells also confirmed these cells’ ability 
to proliferate and differentiate under biological conditions. My thesis, therefore, proves 
both the entrance into, and biologically accurate function of, induced hematopoietic 
progenitors (iHP) from a varied source of murine fibroblasts. 
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1.1. THE HEMATOPOIETIC SYSTEM 
Our understanding of human development and its systems is predicated upon the idea of a 
stepwise progression in which a totipotent cell gradually restricts in its potential until a 
terminally differentiated cell fate is achieved. This idea holds true on both an organism-
wide scale and within a specific organ system. In the case of the hematopoietic system, 
there exists a stem cell with the potential for both self-renewal and all the mature cells 
collectively called blood. 
The hematopoietic system is one of the first complex tissue systems to develop and be 
employed in the mammalian embryo. Due to its importance to life, it has become one of 
the most well studied tissue systems, with knowledge being accrued from over more than 
50 years of study. As early as the 1960s, when the first formal search began for the HSC 
in bone marrow, Till and McCulloch (Till and McCulloch 1961) defined what remains to 
this day as two hallmarks of a HSC: the ability to self-renew, and the ability to give rise 
to all the different cell types of blood cells.  
The hematopoietic system is also one of the best-studied systems as it serves as a model 
for understanding somatic stem cells and how they mature and differentiate. As mature 
blood cells are relatively short-lived, the HSC is required throughout life to replenish the 
various progenitors, with several or single lineage potential, which go on to generate all 
the mature cells in blood. This protracted window of existence has allowed the 
hematopoietic system to be studied in detail from its cell of origin, through to the mature 
cells, thus permitting a look into stem cell differentiation, tissue system aging, and niche 
controlled differentiation, amongst other nuggets of insight about our biology gleaned 
from the study of this system. 
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Early studies done trying to identify the HSC occurred during the 1960’s (Till and 
McCulloch 1961; Wu et al. 1967; Schofield 1978; Becker et al. 1963), and ultimately was 
the first tissue-specific stem cell to be, prospectively, isolated in 1988 (Spangrude et al.). 
Till and McCulloch in 1961, first demonstrated, quantifiably, the clonal multilineage 
potential of an undifferentiated hematopoietic cell, later shown to be more committed 
progenitors (Schofield 1978). The HSCs were found and quantified through arduous 
transplantation experiments in which mice were irradiated, injected with limiting 
dilutions of bone marrow (BM) cells, and then examined for repopulation of the 
hematopoietic lineage. These early studies were able to identify a 0.1% frequency of 
cells, from total BM, able to repopulate adult irradiated mice (Szilvassy et al. 1990). 
Moreover, the HSC was also identified by their differentiation potential through colony 
forming cell assays. This differentiation assay revealed that only a very small percentage 
of bone marrow cells were capable of forming colonies that contained more than one cell 
type, and in some cases, all cell types of the myeloid lineage. Building off of these early 
studies, our understanding of the identity of the HSC has expanded to include cell surface 
markers. These advances have enabled us to not only isolate the HSC, but to identify it 
without losing the stem cell potential.  
 
1.1.1. DURING DEVELOPMENT 
YOLK SAC 
Unlike other organ systems, the hematopoietic system begins forming at multiple sites 
during embryonic development (Figure 1). It is currently believed that there are two 
distinct sites of hematopoiesis during development, the yolk sac and the embryo body 
proper, as determined by chick and quail embryo grafting experiments (Dieterlen-Lievre 
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1975; Lassila et al. 1982). During early development, prior to the onset of circulation, the 
yolk sac generates the primitive hematopoietic system, mainly the primitive erythroid 
program. It is therefore, the earliest site of hematopoietic development (Sabin 1920). 
Blood islands in the yolk sac arise around embryonic day 7.5 (E7.5) and are comprised of 
embryonic erythroid cells and their progenitors. Various independent differentiation 
experiments of in vitro totipotent mouse ESCs have identified the hemangioblast as the 
origin of blood islands in the yolk sac, and thus the very first hematopoietic progenitor 
during mammalian development (Choi et al. 1998). These hemangioblasts are believed to 
be responsible for the formation of both the primitive red blood cells as well as some of 
the early yolk sac vasculature (Ferkowicz and Yoder 2005; Ueno and Weissman 2006). 
AORTA, GONAD, MESONEPHROS (AGM) 
The second site of hematopoiesis occurs after circulation begins in the AGM (Medvinsky 
and Dzierzak 1996) around E10.5. This site generates the definitive hematopoietic 
program, in which all lineages are represented, including the lymphoid program. The 
appearance of the full hematopoietic program at this time leads to the current idea of the 
AGM being the birthplace of the definitive HSC. Unique to the definitive hematopoietic 
system is the ability to reconstitute the hematopoietic system in its entirety during 
transplantation studies. Various studies done on hematopoietic populations from different 
times during development have identified a population able to reconstruct both the 
myeloid and lymphoid programs when introduced into an irradiated mouse recipient. This 
ability to reconstitute the hematopoietic system is not evident prior to the onset of 
circulation, when the yolk sac and primitive hematopoietic system are dominant in the 
embryo (Cumano et al. 1996).  
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Two distinct characteristics of having passed into the definitive hematopoietic program, 
is the ability to fully reconstitute the hematopoietic system (Müller et al. 1994), upon 
transplantation into an irradiated adult mouse, and the appearance of lymphoid potential 
(Godin et al. 1995; Lacaud et al. 1998) in the developing fetus. Other definable 
differences between the definitive and primitive hematopoietic program lie within the 
erythroid lineage. Primitive erythroid cells are distinctly larger than their definitive 
counterparts, and are nucleated, whereas definitive erythroid cells are small, enucleated 
and express adult hemoglobin (Russell 1979; Barker 1968; Brotherton et al. 1979).  
It would seem the AGM itself has the ability to generate adult-repopulating HSCs from 
the ventral endothelium of the dorsal aorta (Medvinsky and Dzierzak 1996; Taoudi and 
Medvinsky 2007; North et al. 2002; de Bruijn 2000). In fact, presumptive HSC clusters 
found attached to the wall of the AGM are CD45+ (North et al. 2002), sca-1+ (de Bruijn et 
al. 2002), c-Kit+cd34+ (Sánchez et al. 1996), Runx-1+ (North et al. 2002), and Scl+ 
(Sánchez et al. 2001). All of these markers are indicative of the hematopoietic program, 
and, with the exception of CD45, are important in identifying the adult HSC. Once AGM 
HSCs are detected, HSCs are also detected soon after in a variety of other organs, 
including the fetal liver, yolk sac, and placenta (Taoudi et al. 2005). Colonization of the 
fetal liver by AGM-derived HSCs is detectable at E10.5, at which time they expand and 
differentiate into the mature components of the hematopoietic system.  
FETAL LIVER 
Fetal liver is commonly held to be a major site of hematopoiesis from E11.5 until birth, at 
which point HSCs from both the liver and AGM migrate into the bone marrow, which is 
the hematopoietic origin throughout adulthood. These two distinct niches cater to the 
needs of the organism at discrete times. One very clear difference between these two sites 
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lies in the fact that in fetal liver, HSCs are continuously cycling, whereas within the bone 
marrow niche, HSCs are largely quiescent (Orkin and Zon 2008). Within both the fetal 
liver and the bone marrow HSCs exhibit all other characteristics, including the ability to 
differentiate into both the myeloid and lymphoid lineage as well as the ability to stably 
and multilineagely reconstitute the blood program in an irradiated adult mouse. The 
relationship between these two niches are fairly intertwined as it is believed that HSCs 
from fetal liver migrate to the bone marrow at or around birth and thus colonize the bone 
marrow niche, thus making bone marrow the site of adult hematopoiesis (Orkin and Zon 
2008). However, there is also an argument that these two niches are colonized at the same 
time during development, but that they are employed at different times (Delassus and 
Cumano 1996). This matter has yet to be clarified, as there is evidence to support both. 
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Figure 1: Hematopoiesis during development. B) Schematic representation of the different sites of hematopoiesis 
during development, wherein, different locations favor the production of specific blood lineages. Abbreviations: ECs, 
endothelial cells; RBCs, red blood cells; LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-term 
hematopoietic stem cells; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; MEP, 
megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progenitor; C) Developmental time windows for 
each site of hematopoiesis; Figure adapted from (Orkin and Zon 2008).  
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1.1.2. HEMATOPOIETIC STEM CELL (HSC) 
The hematopoietic system (Figure 2) is specifically maintained by a small population of 
pluripotent so-called hematopoietic stem cells (Becker et al. 1963). HSCs reside in the 
bone marrow in adulthood, can differentiate into every hematopoietic cell type 
(Spangrude et at. 1988), and persist for the entire lifetime of an animal, beginning with 
development, in order to continually maintain the hematopoietic system (Harrison 1979). 
Upon transfer of HSCs into radio-ablated hosts, even a single HSC can repopulate the 
entire hematopoietic system and reinstate steady-state hematopoiesis (Osawa et al. 1996; 
Spangrude et al. 1988; Thomas et al. 1959). Their multilineage differentiation ability to 
flexibly generate all hematopoietic cell types label them as multipotent, and their ability 
to continually proliferate for an entire lifetime reaffirms that they may self-renew—thus, 
HSCs are bona fide stem cells (Ramalho-Santos and Willenbring 2007). 
Within the stem cell tier of the hematopoietic lineage, there are two types classified as 
long-term and short-term stem cells. This classification originated when it was found that 
a smaller percentage of the cells capable of reconstituting irradiated mice (identified to be 
of short-term stem cell capability) were able to serially reconstitute yet another mouse. 
This ability for long-term propagation was thus characterized as the defining trait of the 
long-term HSC. The capacity to serially reconstitute irradiated adult mice is generally 
taken as evidence of self-renewal, even though this potential has not yet been 
demonstrated in vitro. However even the long-term HSC (LT-HSC) has a limit of 4-5 
serial transplants before it too loses the ability to self-renew (Allsopp et al. 2003b; 
Allsopp et al. 2003a; Spangrude et al. 1995). As per the ‘clonal succession model’, it is 
believed that LT-HSC spend majority of their time in a somewhat quiescent state in 
which they divide at a much slower rate than the other progenitors (Kay 1965). The LT-
HSC is thus found at low frequency of between 1 in 100,000 to 1 in 10,000 cells in the 
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bone marrow (Chao et al. 2008; Luc et al. 2008; Orkin and Zon 2008). These LT-HSC 
are believed to give rise to the ST-HSC population within the bone marrow niche. Both 
the LT-HSC and the ST-HSC have the ability to self-renew and differentiate, however, 
the self-renewing capability of the LT-HSC is significantly greater than the ST-HSC as 
the ST-HSC does not have the ability to sustain serial repopulation (Yang et al. 2005). 
Moreover, it is believed that the LT-HSC could serve as a ‘reserve force’ for the 
hematopoietic system, which is mobilized when there is a stress on the system, such as in 
the case of traumatic blood loss (Morrison et al. 1995).  
 
1.1.3. RESTRICTED PROGENITORS 
The next tier on the hematopoietic hierarchy is rather controversial (Figure 2). Its 
existence is questioned, as differentiation and transplantation assays are unable to 
discriminate between subpopulations of cells that have the capability to produce the 
entire hematopoietic system. The LT-HSC, the ST-HSC, as well as the multipotent 
progenitors (MPPs) all have the ability to recapitulate the successive generations of cells 
which make up the players of the hematopoietic system, however, the vital difference 
between these three subpopulations lie within their capacity to self-renew. MPPs 
themselves are not able to self-renew (Adolfsson et al. 2001; Christensen and Weissman 
2001), unlike the LT/ST-HSCs. To some, this difference warrants a discrete class 
distinction while others do not agree due in large part to the relative unfamiliarity with 
other identifying characteristics, such as surface markers or expression profiles.  
The MPP is the last tier in which both major arms of the hematopoietic system, the 
lymphoid and myeloid lineages are represented within one cell. One step below the MPP 
lays the common myeloid (CMP) and the common lymphoid progenitor (CLP). These 
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progenitors are solely responsible for, as their name suggests, the myeloid or the 
lymphoid lineages. It is notable that as of this point, we see the first restriction in 
potential coinciding with the loss of one of the stem cell surface markers, Sca-1. This is 
also the earliest point on the hierarchy that is detectable within the in vitro differentiation 
assay, the colony forming cell (CFC) assay, as the differentiation assay is unable detect 
the ability to self-renew (Chao et al. 2008).  
 
1.1.4. COMMITTED PROGENITORS AND MATURE CELLS. 
From the myeloid lineage stems the greatest range in mature cell types (Figure 2). It is a 
well-studied system, and contains some of the most useful mature cell types in trauma. 
Directly below the CMP lie the bi-potential progenitors, known as the Granulocyte-
Monocyte progenitor (GMP) and the Erythrocyte-Megakaryocyte progenitor (EMP). The 
GMP progresses into the uni-potential progenitors each of whom are responsible for 
either granulocytes or macrophages. Likewise the EMP also develop into uni-potential 
progenitors, these produce the erythrocytes, red blood cells, and megakaryocytes, the 
origins of platelets (Akashi et al. 2000; Forsberg et al. 2006; Nakorn et al. 2003).  
The lymphoid lineage also progresses from the CLP through uni-potential progenitors of 
the B and T cell types (Karsunky et al. 2008). This lineage is responsible for the 
production of B, T, and natural-killer (NK) cells, all of who are responsible for our 
immune system. As important as the erythrocytes, which carry oxygen throughout the 
body, is the basic ability to fight off invaders. Without the lymphoid system, we are at the 
mercy of our environment, much like those suffering from AIDS, and various other 
immunological deficiencies, face daily.  
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Mature cells of both the myeloid and lymphoid lineages have identifying characteristics. 
Myeloid cells have morphological as well as surface marker expression to distinguish the 
many different mature myeloid cell types. Lymphoid cells have surface marker 
expression to identify the different subsets of mature B and T-cells. These characteristics 










1.2.1. SOMATIC CELL NUCLEAR TRANSFER (SCNT) 
The concept of nuclear plasticity has had a long and meandering history. Beginning in 
1918, when Dr. Hans Spermann, a developmental biologist at the University of Freiberg, 
proved the totipotency of a single nucleus in a 16-cell salamander embryo. He later 
hypothesized in 1938, that differentiated cells are fundamentally plastic in nature and 
could be proven through use of nuclear transplantation techniques, such as somatic cell 
nuclear transfer (SCNT; as reviewed by Graf 2011). It wasn’t until 1952 that Briggs and 
King were able to successfully demonstrate this technique using Rana pipiens (Briggs 
and King 1952). However, as they found that only nuclei from blastula, and not from 
more differentiated cells, were able to generate proper tadpoles, they concluded it was 
impossible to generate clones from the nucleus of an adult cell as the inherent potential 
declines during development (King and Briggs 1955). John Gurdon later challenged this 
conclusion just a few years later. Using Xenopus laevis, Gurdon was able to generate 
mature animals from nuclear transfer of tadpole intestinal cell nuclei, thus proving Briggs 
and King’s contention of diminishing inherent totipotency wrong (Gurdon et al. 1958; 
Gurdon and Uehlinger 1966). The major conclusion from these, and subsequent studies, 
was that development and differentiation imposed reversible epigenetic changes, rather 
than irreversible genetic changes, resulting in a particular cellular identity. 
Thirty years would pass before SCNT was successfully used to clone other vertebrate 
species, beginning with Dolly the sheep. Dolly was cloned through transplantation of the 
nuclei of cultured epithelial cells into enucleated oocytes (Wilmut et al. 1997). A year 
later saw the first successful cloned mice derived from nuclear transfer of cumulous cell 
nuclei (Wakayama et al. 1998). More importantly, by using B and T-cell nuclei, 
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Hochedlinger and Jaenisch were able to prove the generation of viable mice from only 
the transferred nuclei by probing for the immunoglobin, or T-cell receptor 
rearrangements in the cloned animals (Hochedlinger and Jaenisch 2002). A study done 
last year, generating stable triploid human ESC lines from skin cell-derived nuclei 
transplanted into nucleated oocytes, showed that it is possible to reprogram human 
somatic cells using SCNT (Noggle et al. 2011). Nevertheless, while SCNT studies 
showed that even terminally differentiated cells remain genetically totipotent, most 
cloned animals exhibit subtle to severe phenotypic and gene expression abnormalities, 
suggesting an imperfect epigenetic reprogramming (Wakayama and Yanagimachi 1999; 
Stadtfeld and Hochedlinger 2010; Humpherys et al. 2002; Ogonuki et al. 2002; 
Tamashiro et al. 2002; Gurdon et al. 2003). 
 
1.2.2. INDUCED PLURIPOTENT STEM CELL (IPS) 
Directed induced pluripotent stem cell (iPS) generation through selected nuclear 
transcription factor (TF) overexpression is ethically and technically less problematic than 
SCNT. Two major breakthroughs allowed for the success of this method. First was the 
establishment of mouse ESC lines (Evans and Kaufman 1981; Martin 1981); and 17 
years later, human ESC lines (Thomson et al. 1998). Second was the realization that 
lineage associated transcription factors not only help to establish and maintain cellular 
identity but, when ectopically expressed in certain cells, were able to change cell fate.  
The power of TFs in determining cellular identity was first demonstrated by the 
formation of myofibers in fibroblast cell lines transduced with viral vectors expressing 
MyoD (Davis et al. 1987). More recently, sets of TFs have been identified capable of 
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inducing the conversion of pancreatic acinar cells into insulin-producing β-cells by 
overexpression of pancreatic factors MafA, Pdx1, and Ngn3 (Zhou et al. 2008). 
Conversion of fibroblasts into neurons by overexpression of neural factors Ascl1, Brn2, 
and Myt1l (Vierbuchen et al. 2010); and the conversion of fibroblasts into 
cardiomyocytes by cardiac factors Gata4, Mef2c, and Tbx5 (Ieda et al. 2010) have also 
been achieved. While these reprogramming events cross germ layer delineations, 
mesoderm-derived fibroblasts into ectoderm-derived neurons, the pluripotent state was 
only shown in 2006. 
 iPS were created using the pluripotency associated TFs: Oct4, Sox2, c-Myc and Klf4 
(Nakagawa et al. 2008; Takahashi and Yamanaka 2006). However, as this “first-
generation” iPS was unable to generate chimeric mice or exhibit germ line transmission, 
it appeared the reprogramming was incomplete. Improvements were not far behind, 
generating iPS with epigenetic patterning and functionality more closely resembling ESC 
(Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007). More recently, iPS lines 
have been identified that are capable of producing “all-iPS” mice (Boland et al. 2009; 
Kang et al. 2009; Zhao et al. 2008), the best indication of ESC potency in at least some 
iPS lines (Stadtfeld and Hochedlinger 2010).  
The generation of iPS cell lines is not limited to just mouse and human (Takahashi et al. 
2007; Yu et al. 2007; Park et al. 2008). The use of the four Yamanaka factors has 
successfully produced iPS in rats (Li et al. 2009) and rhesus monkeys (Liu et al. 2008), 
demonstrating the evolutionarily conserved nature of the regulation of the pluripotency 
transcriptional network. Additionally, iPS have also been generated from a plethora of 
other somatic cell types, such as keratinocytes (Aasen et al. 2008; Maherali et al. 2008), 
neural cells (Eminli et al. 2008; Kim et al. 2008), stomach and liver cells (Aoi et al. 
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2008), melanocytes (Utikal et al. 2009b), and even terminally differentiated lymphocytes 
(Hanna et al. 2008; Eminli et al. 2009). These discoveries of the malleability of cell 
identity through viral-induced overexpression of specific nuclear TFs has opened the 
discipline up to inducing other lineage-specific stem cells.  
 
1.2.3. HEMATOPOIETIC REPROGRAMMING 
Within the hematopoietic lineage, trans-differentiation between myeloid and lymphoid 
lineages is not new (Figure 3). In fact, only one year after the discovery of MyoD 
overexpression converting mouse embryonic fibroblasts (MEFs) into myoblasts, the 
overexpression of n-Myc and c-Raf (Klinken et al. 1988) was able to convert B 
lymphocytes into macrophages. Moreover the overexpression of C/EBPα is sufficient to 
trans-differentiate a lymphoid progenitor into a functionally mature macrophage cell 
(Laiosa et al. 2006; Xie et al. 2004). So in the context of the hematopoietic system, 
reprogramming is not new. However, for all that is known about the hematopoietic 
system, we are only now beginning to venture into the realm of reprogramming into the 
HSC. In 2010, Bhatia’s lab published their results in creating the first induced HSC 
(iHSC). They found, surprisingly, that overexpression of OCT4 in conjunction with 
culture conditions optimized to sustain hematopoietic cell proliferation was able to 





Figure 3. Reprogramming within the hematopoietic system. Arrows illustrate direct reprogramming from the 
myeloid lineage into the lymphoid lineage, and vice versa, by forced expression of the indicated transcription factor. 




1.3. TRANSCRIPTION FACTORS 
According to literature, transcription factors (TFs) are the key to cell identity (Tam and 
Lim 2008; Chambers and Tomlinson 2009). To that end the hematopoietic system enjoys 
the advantages of being one of the longest and most well characterized lineages. Over 70 
years of studies have accrued a vast reserve of knowledge from vital TFs crucial to the 
formation of cell types, to cell surface marker combinations that allow scientists to 
identify cell types. Many of the current cadre of key hematopoietic TFs were discovered 
by their involvement in leukemia, such as MLL (for mixed lineage-leukemia gene; Orkin 
2000; Krivtsov et al. 2006), Runx1 (North et al. 1999; North et al. 2002), Tel/ Etv6 (Hock 
et al. 2004; Wang et al. 1998), Scl/Tal1 (Porcher et al. 1996; Hall et al. 2003), and Lmo2 
(Kim and Bresnick 2007). Numerous others have been discovered through extensive 
knockout studies. A summary of TFs found to be crucial to the hematopoietic system can 
be seen below in (Orkin and Zon 2008).  
In mice, these studies have led to the classification of a stem cell class of TFs that are 
responsible for either the formation, or proliferation of the HSC. For example, ablation of 
expression of Scl/Tal1 or Lmo2 during development leads to a complete absence of HSC 
formation (Robb et al. 1996; Yamada et al. 1998). Within this class of factors lie the 
well-studied trio of Scl, Lmo2, and Runx1, found to be absolutely crucial to the 
formation of the definitive HSC during fetal development. Moreover, these factors have 
been proven to be key in maintaining the HSC population during the lifespan. Other 
factors important to either the formation or proliferation of the HSC include Gata2, 
Hoxb4, Bmi1, and Gfi1 (Orkin and Zon 2008).  
Further downstream of the HSC, at the multipotent progenitor stage, crucial TFs 
responsible for specific cell types within the myeloid or lymphoid lineage have also been 
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elucidated. One example is PU.1, in which the absence of PU.1 expression in the GMP 
prevents the entire granulocyte or macrophage mature cell types from forming (Galloway 
et al. 2005). The lack of PU.1 expression in the CLP also results in a loss of mature 
lymphoid cell differentiation (Rhodes et al. 2005). Likewise, the knockdown of C/EBPα 
in the GMP only leads to an absence of mature eosinophil and neutrophil differentiation 
(Querfurth et al. 2000). Finally, the lack of Gfi1 expression during hematopoietic 
differentiation results in an absence of neutrophil precursors, and perturbs the normal 
expression of the monocyte/macrophage cadre of genes (Hock et al. 2003).  
While these factors may be classified as HSC TFs, their expression is not necessarily 
limited to the HSC. Many of these factors are still expressed within the restricted and 
committed progenitors (Akashi et al. 2000). Vice versa, those TFs important for the 
differentiation into mature cells are also expressed, albeit at low levels, in the HSC (Hu et 
al. 1997; Enver and Greaves 1998). This merely highlights the importance of these 
factors to the hematopoietic system and the difficulty in the reliance of expression studies 
in identifying the many subsets of cells within this highly complex lineage. Below, I 
emphasized 4 TFs known to be critical in either the derivation of, or maintenance of the 
HSC, and worth a more detailed explanation of their importance and significance within 




Figure 4. Transcription factor requirements of the hematopoietic system. Red bars indicate crucial transcription 
factors required for development of downstream cells as determined by conventional gene knockout studies. Figure 





Scl/Tal1, a basic Helix-loop-helix protein, is one of the earliest transcriptional markers 
known to indicate entry into the hematopoietic lineage in development (Mikkola et al. 
2003). In mouse, the positive expression of Brachyury designates the formation of the 
primitive streak, from which Scl expression specifies the hematopoietic and endothelial 
lineage, with expression of Gata1 denoting hematopoietic commitment (Endoh et al. 
2002). Scl/Tal1 has been proposed to be the ‘master regulator’ of hematopoiesis due to its 
vital role in the development of both the primitive and definitive hematopoietic systems 
(Kim and Bresnick 2007). In its absence or the absence of Lmo2, no blood cells are 
formed, either in the yolk sac (Robb et al. 1995) or the embryo proper (Shivdasani et al. 
1995). Interestingly, while Scl is crucial for the initiation of hematopoiesis in the AGM 
(Robb et al. 1996), it is expendable for the function of adult HSCs in bone marrow 
(Mikkola et al. 2003). The Scl-Lmo2 complex has also been shown to regulate the 
expression of c-Kit, the stem-cell factor (or steel factor) receptor, which helps to maintain 
cells in a proliferative state (Loose et al. 2007). This is of great interest as c-Kit 




Lmo2, a known associate of Scl/tal-1, is also of vital importance to the formation of 
blood (Kim and Bresnick 2007). This Lim-domain containing protein, serves as a bridge 
in the Scl/tal-1 complex linking it to the Gata1/2 component of the complex (Loose et al. 
2007). In morpholino knockdown experiments done in zebrafish, modified Scl unable to 
interact with Lmo2 were unable to rescue the knockdown, emphasizing the importance of 
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this association (Patterson et al. 2007). In mouse, the importance of the Scl-Lmo2 
interaction in forming the initial HSC is also well documented - it has been shown that 
Runx-1 is a direct target of this complex (Landry et al. 2008). Ultimately, the measure of 
the significance of any TFs lies within knockout studies, and the knockdown of either Scl 
or Lmo2 results in an absence of blood cells (Shivdasani et al. 1995; Yamada et al. 1998), 




For the formation of the definitive HSC, runt-domain Runx-1 (also known as acute 
myeloid leukemia 1 protein; AML1) has also been implicated as a crucial TF (Okuda et 
al. 1996; Sasaki et al. 1996; Wang et al. 1996b; Wang et al. 1996a; Komori et al. 1997; 
Otto et al. 1997; Levanon et al. 2002; Li et al. 2002). Runx-1 knock-down in mice results 
in embryonic lethality around E12.5 and E13.5 (Okuda et al. 1996; Sasaki et al. 1996; 
Wang et al. 1996b; Wang et al. 1996a; Cai et al. 2000), with little to no hematopoietic 
progenitor presence in fetal liver or yolk sac, and more importantly, no cells capable of 
engrafting in adult mice upon transplantation. Similar to what we know of the origins of 
the definitive HSC in developing embryos, Runx-1 expression patterns are also found in 
several distinct embryonic sites such as the yolk sac, and AGM (North et al. 1999; 
Mukouyama et al. 2000; Yokomizo et al. 2000). Its expression also mimics the 
expression pattern of Scl, lending confirmation to the idea of a hemangioblast (Silver and 
Palis 1997; Elefanty et al. 1999). One key difference to note between the lack of 
expression of Scl or Lmo2, and Runx-1, is that the absence of Runx-1 expression during 
development does not affect the emergence of the initial primitive hematopoietic 
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program; rather it impedes only the definitive hematopoietic program (Lacaud et al. 
2002; Okuda et al. 1996; Wang et al. 1996b). This is exemplified by the fact that the 
E10.5 population of HSCs, from AGM, capable of engrafting adult mice was all found to 
express Runx-1 (North et al. 2002), and the lack of Runx-1 expression during this time led 
to an absence of HSC formation within the AGM (Orkin 2000). Moreover Runx-1 is also 
required for the formation of c-Kit+ and CD45+ hematopoietic clusters in the AGM region 
(North et al. 1999; Yokomizo et al. 2000). Thus Runx-1 joins the ranks of Scl/Tal1 and 
Lmo2 as crucial TFs for the formation of the HSC.  
 
1.3.4. HOXB4 
The Hox family of genes has also enjoyed a link to HSC cell cycle regulation. They were 
highly expressed in immature hematopoietic cells, and both knock-down and 
overexpression of select members have been shown to affect entry into the hematopoietic 
lineage, through ES differentiation (Antonchuk et al. 2002), as well as proliferation of 
primary HSC in vitro and in vivo. For example, overexpression of Hoxb3 seems to cause 
an expansion of the myeloid lineage with an incurred cost of the lymphoid lineage 
(Sauvageau et al. 1996). Overexpression of Hoxb4, both enhances ex vivo mouse HSC 
proliferation (Antonchuk et al. 2002), in the presence of hematopoietic cytokines, as well 
as improves the in vivo repopulating ability of HSCs (Sauvageau et al. 1995). In mouse, 
Hoxb4 over expression has been shown to selectively expand the pool of multipotential 
progenitors when assayed under in vitro colony assays as well as in vivo transplant assays 
(Daley 2003). More importantly the overexpression of Hoxb4 in mouse HSC pools does 
not adversely affect the normal differentiation of the HSC; overexpression does not cause 
leukemia in mice (Daley 2003).  
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HOXB gene cluster expression in human HSCs has been well studied. These studies have 
shown that human CD34+ HSCs population highly expresses HOXB4 (Lawrence et al. 
1996). RT-PCR studies corroborate this expression in mouse, more specifically, its 
expression in definitive HSCs, as it does not seem to be detected in yolk sac-derived 
hematopoietic progenitors.  
Interestingly, forced expression of Hoxb4 in yolk sac-derived progenitors was able to 
confer definitive HSC characteristics, specifically the ability to engraft adult mice in 
transplant assays. This suggests the critical nature of Hoxb4 expression in the transition 
from primitive to definitive hematopoietic program (Daley 2003).  
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1.4. IN VITRO HEMATOPOIETIC CELL CULTURE. 
As with all cell culture, the importance of the appropriate culture conditions cannot be 
overlooked. Stem cells depend on their microenvironment to regulate self-renewal and 
differentiation. This concept of a niche has been well explored within the hematopoietic 
system, especially in ex vivo culture of the HSC (Zhang et al. 2003b; reviewed by Moore 
and Lemischka 2006). As there are different sites of hematopoiesis during development 
and adulthood, the HSC niche also changes. However, due to the extensive time the bone 
marrow niche is employed, this environment has garnered the majority of the attention. 
Various studies have identified two seemingly distinct niches in which HSC reside within 
bone marrow (Figure 5), either adjacent to osteoblasts (Sipkins et al. 2005; Calvi et al. 
2003; Zhang et al. 2003b) or adjacent to vascular cells (also called the vascular niche; 
Kiel and Morrison 2006). However, since these two niches are very closely linked, the 
conclusion can be made that the sub regions in which HSCs reside in bone marrow may 
convey only small differences in activity. For our purposes, the traditional osteoblast 
niche is of greater importance since recent research has shown that HSC are kept in a 
quiescent state when interacting with the thrombopoietin (TPO)-producing osteoblasts 
(Yoshihara et al. 2007). Within the bone marrow also reside stromal cells that produce a 





Figure 5. Adult bone marrow hematopoietic stem cell niche. HSCs are found within two distinct niches in bone 
marrow, the osteoblast niche or the vascular niche. The osteoblast niche is under regulation by bone morphogenetic 
protein (BMP), and is associated with quiescent HSCs. The vascular niche is found adjacent to blood vessels where 
CXCL12 regulates migration of HSCs from circulation into bone marrow. Within the bone marrow space stromal cells 
support hematopoiesis by producing cytokines, i.e. c-Kit ligand, which stimulates stem cells and progenitors. Figure 
from (Orkin and Zon 2008). 
 
! ! !!27!
1.4.1. FEEDER LAYER 
The use of stromal cells in hematopoietic ex vivo culture has enjoyed a rather illustrious 
history. Stromal cells isolated from the AGM have displayed the ability to support 
expansion of somatic HSCs as well as the generation of definitive HSCs from mouse 
early yolk sac (Oostendorp et al. 2002; Matsuoka et al. 2001) AGM derived stromal cell 
lines have also been successful in supporting hematopoietic differentiation of mouse 
embryonic stem cells (Weisel et al. 2006; Krassowska et al. 2006).  
The OP9 stromal cell line is derived from macrophage-colony stimulating factor (M-
CSF) deficient newborn op/op mice (Yoshida et al. 1990; Nakano et al.1994). One of the 
advantages conferred by using the OP9 line over other AGM derived lines is that OP9 
seems to inhibit apoptosis and also enhance the proliferation of hematopoietic precursors 
(Ji et al. 2008). The OP9 stromal cells have also been proven to support the 
differentiation of murine and other primate embryonic stem cells into the hematopoietic 
lineage (Nakano et al. 1994; Umeda et al. 2004). Currently this line is most utilized for its 
ability to direct or ‘prime’ ESC into the hematopoietic lineage (Eilken et al. 2009; 
Fujimoto et al. 2001; Nakano et al. 1996; Keller 2005). For our purposes, this line also 
afforded us an opportunity for early assessment of the identity of our cells, through the 
cobblestone area forming cell assay (CAFC), which will be discussed in more detail later.  
 
1.4.2. CYTOKINES 
Another aspect of cell culture involved the simulation of cell signals through the addition 
of cytokines. In the context of the ESC state, important cytokines include leukemia 
inhibitory factor (LIF) for mESC, and fibroblast growth factor (FGF-1) for human ESC 
! ! !!28!
culture. The various roles of hematopoietic cytokines have been elucidated through 
numerous differentiation assays utilizing ESC in combination with OP9 in co-culture 
(Figure 6). For example, the addition of TPO, interleukin (IL)-6, and IL-11 to the co-
culture of mESC with OP9 resulted in the production of megakaryocytes that produced 
pro-platelets (Eto et al. 2002). Similarly, the addition of erythropoietin (EPO) into the co-
culture of mESCs and OP9 generated erythroid cells (Otani et al. 2004). For HSC culture, 
various combinations of cytokines have been shown to be successful in both maintaining 
and expanding HSCs in vitro. More specifically, the commonly used panel of cytokines 
comprising stem cell factor (steel factor, SCF), IL-3, TPO, and FMS-like tyrosine kinase 
3 ligand (FLT3LG) is known to promote the expansion of primitive hematopoietic 
progenitors (Holyoake et al. 1996; C. L. Miller and Eaves 1997; Nakano et al. 1994; 
Sitnicka et al. 1996). It has been shown that SCF, TPO and IL-3 together act directly 




Figure 6. Hematopoietic cytokines. Diagram depicting some of the important hematopoietic cytokines determining 
differentiation into specific cell types. Abbreviations: SCF, stem cell factor; TPO, thrombopoietin; IL, interleukin; GM-
CSF, granulocyte/macrophage colony stimulating factor; EPO, erythropoietin; M-CSF, macrophage colony stimulating 
factor; G-CSF, granulocyte colony stimulating factor; SDF-1, stromal cell derived factor 1; FLT-3 ligand, FMS-like 





1.5. IN VITRO HEMATOPOIETIC CELL ASSAYS. 
Within the hematopoietic field there are many different methods one can employ to 
identify the many progenitors and mature cells that comprise this lineage. Historically 
hematopoietic progenitors were identified by their colony morphology under appropriate 
culture conditions, by their differentiation ability in semi-solid media, or by their 
engraftment potential in transplant assays. More recently, progenitors and their mature 
counterparts have been increasingly identified through their expression of specific cell 
surface markers and fluorescence-activated cell sorting (FACS) analysis. Mature cells of 
the hematopoietic lineage also show clear nuclear morphology that is distinctive through 
staining with Wright-Giemsa, or benzidine for erythroid. With this method, the different 
types of mature blood cells are distinguishable.  
 
1.5.1. COBBLESTONE AREA FORMING CELL ASSAY (CAFC) 
This assay is modeled off of the original limiting dilution assays done to determine the 
frequency of progenitors capable of repopulating adult mice in subsequent transplants 
(Ploemacher et al. 1991). It employs the use of a stromal feeder layer co-culture as well 
as the addition of cytokines to assess the morphology of resulting colonies. Since the OP9 
stromal cell line together with the addition of SCF, FLT3LG, IL-3 and TPO, has proven 
itself to be able to support the differentiation of ESCs into the hematopoietic lineage 
(Keller 1995), we utilized these culture conditions to assess the quality of our 
reprogrammed cells by observing their ability to perform within the constraints of this 
assay.  
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Simply, bone marrow cells introduced onto a layer of irradiated stromal cell feeder layer 
in the presence of hematopoietic cytokines, form colonies with distinct morphology 
(Figure 7). Any primitive cells found in the bone marrow population migrate through the 
stromal layer, where they proliferate in a time-dependent manner according to their 
primitiveness (Down and Ploemacher 1993). Cultures are screened at serial time points 
post-seeding for the presence of “cobblestone areas”. These cobblestone areas are defined 
to be of at least 5, small, non-refractile cells that grow beneath the stromal layer. The 
morphology of these cells are said to be akin in appearance to cobblestone found on roads 
in days of yore, hence named likewise. At 7 days after seeding, it was found that any 
cobblestone colonies present in culture are comprised of restricted or committed 
progenitors as revealed by their differentiation potential (Down and Ploemacher 1993; 
Ploemacher et al. 1992). Those cobblestone colonies present at 3-5 weeks after seeding 
are indicative of the presence of more primitive progenitors, including progenitors with 
the ability to completely reconstitute the hematopoietic program in an irradiated adult 
mouse (de Haan and Ploemacher 2002; Down et al. 1997). This calculation incorporates 
the assumption that committed progenitors would have differentiated into mature cells 
thus taking the form of suspension cells, leaving only the most primitive progenitors 
forming cobblestone colonies at a later time. A multitude of studies have shown this 
theory to be true, underscored by the idea that this is the basic premise upon which long-
term culture initiating cell assay is based. Moreover, this assertion allowed for 
quantification of the HSC in mouse bone marrow before the discovery of the unique 
combination of cell surface markers favored today.   
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Figure 7. Example of a cobblestone colony from murine bone marrow in cobblestone area forming cell assay. 
True cobblestone colonies are determined by the appearance of at least 5 small non-refractile cells growing beneath the 
stromal layer, in this case flask bone marrow dexter-1 (FBMD-1), as evident in this bright-field image. Image taken 




1.5.2. SURFACE MARKER CHARACTERIZATION BY FACS ANALYSIS. 
In assessing whether we had reprogrammed fibroblasts into cells of hematopoietic 
character, we relied heavily on FACS to characterize the cell surface antigenic profile of 
transduced fibroblasts. Over thirty years of research have assigned definitive antigenic 
profiles of specific hematopoietic cell types (see Scollay et al. 1978 for the first such 
demonstration)—thus, a putative hematopoietic cell’s specific lineage may be readily 
defined by FACS analysis. Such analyses rely on antibodies recognizing specific cell 
surface antigens and using a battery of such antibodies to look for co-expression of 
different diagnostic markers on a cell, therefore defining the specific lineage of a 
hematopoietic cell and identifying the proportion of these cells in a culture. If there is one 
aspect that promotes the use of cell surface markers to identify the various cell types in 
the hematopoietic lineage is the ability to easily quantify the populations. Cell surface 
markers also allow for the clean separation of populations without affecting any 
progenitor potential. Here again we reap the benefits of decades of work.  
Collectively there is a 7-10 antibody combination that marks the many different mature 
cell types within the hematopoietic lineage. This concept of a mature lineage marker was 
first proven with the discovery that B-cell progenitors do not express the B-lineage 
marker B220, the B-cell form of the CD45 molecule (Muller-Sieburg et al. 1986; 
Coffman and Weissman 1981). Thus it was also proposed that the other progenitors 
lacked expression of known mature lineage markers. Due to more than 40 years of study, 
groups working within the hematopoietic field have largely accepted the current list of 
lineage markers (Table 1). CD45/Ly-5 is typically used as a “pan-hematopoietic” marker 
that is expressed by most differentiated hematopoietic cell types (reviewed by Morrison 
et al. 1995), except mature erythrocytes and committed erythroid progenitors (Shiku et al. 
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1975; Thomas 1989). So-called differentiation-associated “lineage” markers typically 
refer to mature erythrocyte marker Ter119, granulocyte marker Gr-1, 
macrophage/monocyte marker CD11b, and lymphoid markers CD3, CD4, and CD8 
indicative of T-cells, and CD19 and B220 indicative of B-cells.  
Undifferentiated mouse HSCs have been classically found to express markers c-Kit and 
Sca1 while not expressing multiple lineage markers (Spangrude et al. 1988; Ikuta and 
Weissman 1992; Morrison and Weissman 1994; Ogawa et al. 1991)—hence HSCs are 
often referred to have an “L-S+K+” antigenic profile (that is, Lineage-, Sca1+, and c-Kit+). 
The LSK population however, includes the LT-HSC and ST-HSC as well as the MPPs 
(Kondo et al. 2002). The discovery of the expression of Flk2/Flt3 receptor tyrosine kinase 
on differentiating HSCs in combination with the knowledge that murine HSCs are CD34-, 
led to the ability to distinguish between these three classes within the LSK population 
(Christensen and Weissman 2001). Therefore, the LT-HSC is now LSK CD34loFlk2lo/-; 
ST-HSC is LSK CD34hiFlk2lo/-; and the MPP being LSK CD34hiFlk2hi (Adolfsson et al. 
2001; Christensen and Weissman 2001; Osawa et al. 1996; Yang et al. 2005). The more 
recent discovery of the SLAM characterization for the HSC, CD150+CD48-CD41-, on 
top of the lineage depletion has only lent a more succinct distinction to this classification 
(Kim et al. 2007; Pronk et al. 2007). This combination does not, it seems, greatly improve 
the purification of the LT-HSC over the older LSK CD34-/Flk2- combination, allowing 
for the interchangeable use of either combination of markers (Ema et al. 2006; Osawa et 
al. 1996).  
The CLP and CMP also carry their own distinct combination of markers allowing them to 
be clearly isolated from the pool of hematopoietic c-Kit+ progenitors. The existence of 
the CLP, which gives rise to the lymphoid system, was hypothesized but unproven for 
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years. In the mouse thymus, Thy-1loc-Kit+ cells were capable of generating all lymphoid 
cells, B, T, NK cells (Wu et al. 1991; Ardavin et al. 1993; Matsuzaki et al. 1993), with no 
evidence of generating myelo-erythorid cells. However, no evidence, as of the late 
1990’s, has shown the existence of a CLP found in bone marrow. We now know that a 
cell marked by Flk2+IL7Rα+Lin-c-Kit+Sca1+ has a clonogenic ability to generate both B 
and T cells. Additionally this cell population lacks any myelo-erythroid potential (Kondo 
et al. 1997). Moreover, the presence of the IL-7 receptor is suggestive and thus not to be 
overlooked, as it is well known that interleukin-7 is an important cytokine for both B and 
T cell development by maintaining cell survival as well as supporting proliferation of 
both the B and T cell progenitors (Peschon et al. 1994; Freeden-Jeffry et al. 1995).  
The existence of the CMP also has had its fair share of controversy, due in large part to 
the difficulty in isolating it from its downstream progeny, GMP and MEP, in accordance 
with the model of progressive lineage restriction as HSCs differentiate into mature 
lineages (Dexter 1990). Extensive work was done to isolate the IL-7Rα- portion of bone 
marrow. Within the Lin-Sca-1-c-Kit+IL7Rα- fraction, cells were highly enriched for 
myelo-erythroid potential (Akashi et al. 2000). This same lab went on to further 
subdivide this population into those capable of only the myeloid and only erythroid 
potential. Consequently, within the Lin-Sca-1-c-Kit+IL7Rα- portion, the CMP is found to 
be CD34+FcγRlo, the GMP to be CD34+FcγRhi, and the MEP to be CD34-FcγRlo. 
Comparable to IL7’s importance in the lymphoid lineage, FcγR-II/III is an important 
marker for myelo-monocytic cells and acts as a progenitor marker in fetal liver 




Table 1. Surface marker combinations used to recognize the hematopoietic lineage. Surface marker combinations 
for multipotent cells are given using both CD34/Flk2(Flt3) and SLAM combinations (in parenthesis). All markers are 
given according to those defined by primary murine cells from either bone marrow (BM), or peripheral blood (PB), and 
spleen. Name! Surface!markers! Location! Source!Multipotent!
 
  
LTOHSC! CD34OFlk2OLinOSca1+cOKit+!(CD150+CD48O)! BM! (Kiel!et!al.!2007;!Goodell!et!al.!1996)!
STOHSC! CD34+Flk2OLinOSca1+cOKit+!(CD150OCD48O)! BM! (Yang!et!al.!2005;!Goodell!et!al.!1996)!MPP! CD34+Flk2+LinOSca1+cOKit+! BM! (Yang!et!al.!2005)!Oligopotent!
 
  CLP! Flk2+IL7Rα+LinOcOKit+Sca1+!BM! (Kondo!et!al.!1997)!CMP! CD34+Thy1OIL7RαOLinOSca1OcOKit+FcγRIlo! BM! (Akashi!et!al.!2000)!MEP! CD34OThy1OIL7RαOLinOSca1OcOKit+FcγRIlo! BM! (Akashi!et!al.!2000)!GMP! CD34+Thy1OIL7RαOLinOSca1OcOKit+FcγRIhi! BM! (Akashi!et!al.!2000)!Mature!
 
  Erythrocyte! CD71+Ter119+! PB!  Megakaryocyte! CD41+CD61+! PB!  Granulocyte! CD45+Gr1+! PB!  Monocyte/Macrophage!!!CD45+CD11b+! PB!  BOcell! CD45+B220+CD19+! PB!  Helper!TOcell! CD45+CD3+CD4+CD8O! PB!  Cytotoxic!TOcell! CD45+CD3+CD4OCD8+! PB!  TOcell! CD45+CD3+CD4OCD8O! PB/!Spleen!  
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1.5.3. COLONY FORMING CELL ASSAY (CFC) 
This assay is an in vitro clonogenic differentiation assay that tests for progenitor 
potential. It employs the use of a semi-solid media and cytokines to generate mature 
differentiated colonies arising from single cells (Figure 8). By examining the clonal 
outgrowth of this assay, subsets of myeloid progenitors have been identified according to 
their progenitor potential (McNiece et al. 1989; Bradley and Metcalf 1966). The 
progenitors that give rise to these colonies are named according to their potential for 
producing mature cells. Therefore, the colony forming unit-granulocyte (CFU-G) is 
indicative of a colony of granulocytes that arose from a uni-potent granulocyte restricted 
progenitor. Likewise, unsorted bone marrow plated into this assay also produced CFU-
macrophage/monocytes (CFU-M), CFU-erythrocytes (CFU-E; Stephenson et al. 1971), 
and CFU-megakaryocytes (CFU-Mk; Metcalf et al. 1975). The cultures were also found 
to generate multilineage colonies, with CFU-GEMM representing the most primitive 
progenitor (where GEMM denotes granulocyte, erythrocyte, macrophage and 
megakaryocyte), thus indicative of the CMP (Johnson and Metcalf 1977; Metcalf et al. 
1979). Present also are the bi-potential GMP, evidenced by CFU-GM comprising both 
granulocytes and macrophages (Ichikawa et al. 1966), and the MEP, represented by CFU-
EM colonies comprised of erythrocytes and megakaryocytes (McLeod et al. 1976). Due 
to the previously stated importance of IL-7 and its involvement in promoting the 
lymphoid lineage, addition of this cytokine to the general mix included in the CFC assay 
does allow for the outgrowth of pre-B-cell colonies (Williams et al. 1990). 
1.5.3.1 NUCLEAR MORPHOLOGY OF MATURE HEMATOPOIETIC CELLS 
Nuclear morphology is very specific to certain differentiated hematopoietic cell types. 
Staining with the Wright-Giemsa stain emphasizes the nucleus as well as any cytoplasmic 
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vacuoles and granules, which are important in assessing identity of macrophage and 
granulocytes. Benzidine, by reacting with hemoglobin is useful in identifying 
erythrocytes, while acetylcholine is useful in detecting megakaryocytes. This ease of 
recognizing mature hematopoietic cells by their nuclear morphology results in this 
procedure still being used in confirming diagnosis of various lymphomas. As seen in 
Figure 8 there are distinct differences in the nuclear morphology of megakaryocytes, 
macrophage, and its monocyte precursor, as well as the many mature types that together 
comprise the granulocytes. Macrophages are easily identified by the pale blue staining of 
their cytoplasm, which contains multiple vacuoles, and purple color of the nucleus, 
frequently compared to a “fried egg”. Monocytes are distinguished by their “kidney-
bean” shaped nucleus, accompanied by a clear spot in the cytoplasm near the bend of the 
nucleus. Within the granulocytes, neutrophils are characterized by a “horse-shoe” shaped 
nucleus; eosinophils by pinkish stained granules in cytoplasm and a bi-lobed nucleus; 
lastly basophils contain dark purple granules in cytoplasm often in such concentration 





Figure 8. Representative CFC assay colonies and nuclear morphology of mature myeloid cells. Left: bright-field 
images of 3 types of myeloid colonies found in CFC assay of normal murine bone marrow. Erythroid burst colony 
forming unit (BFU-E), monocyte/macrophage colony forming unit (CFU-M), and granulocyte/monocyte colony 
forming unit (CFU-GM); Right: illustrations of the mature cells found within these colonies when stained with Wright-
Giemsa in the case of CFU-M and CFU-GM. Note the distinctly different nuclear morphology between the kidney 
bean-shaped monocytic nucleus and the horse-shoe shaped neutrophil nucleus, as well as the distinct “fried-egg” 





1.6. IN VIVO HEMATOPOIETIC CELL ASSAYS. 
The use of in vivo studies has long been tied to hematopoietic research. In fact the search 
for the HSC was prompted by discovery of donor-derived clonogenic, multilineage 
spleen colonies in irradiated mice injected with non-irradiated BM cells (Till and 
McCulloch 1961; Wu et al. 1967). Combined with earlier studies showing injections of 
spleen or BM cells were able to rescue mice from irradiation induced BM failure 
(Jacobson et al. 1951; Lorenz et al. 1952), aided in emphasizing the existence of a cell 
capable of both self-renewal and multilineage differentiation within the BM 
compartment, HSC. Moreover the first practical assay for the identification and 
quantitation of HSCs developed as an in vivo assay identifying “competitive repopulating 
units” (CRU; Szilvassy et al. 1990).  
In the context of reprogramming, in vivo assays are used as a more stringent test of the 
induced cell’s progenitor identity and ability (Szabo et al. 2010); regarding iPS (Shi et al. 
2008; Takahashi and Yamanaka 2006). Likewise, in vivo hematopoietic assays 
interrogate hematopoietic progenitors under conditions that can only be approximated in 
vitro. Differences have been noticed in progenitor differentiation potential under in vitro 
versus in vivo conditions (Ehrlich et al. 2011; Möbest et al. 1999). For example, the 
classic long-term culture-initiating cell assay (LTC-IC) tests for HSCs and progenitors 
capable of initiating long-term bone marrow culture (Dexter et al. 1977) and detectable 
by semi-solid CFC assay (Eaves et al. 1986). However, the LTC-IC assay did not 
accurately measure the extent of self-renewal or range of differentiation the HSC was 
capable of in vivo (Morrison et al. 1995; Sluijs et al. 1992). Additionally in vitro assays 
cannot test for in vivo “homing” capacity, a defining characteristic of HSC (van Os et al. 
2004). Ultimately, in vitro assays cannot capture the full, or biophysically accurate, 
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extent of HSCs and progenitors potential; hence the importance of in vivo assays in 
characterizing induced hematopoietic cells. 
 
1.6.1. SPLEEN COLONY FORMING CELL ASSAY (CFU-S) 
The spleen was first found to be a hematopoietic supportive environment in adult mice in 
the 1950’s when it was observed that mice whose spleens were shielded during radio-
ablation did not die (Jacobson et al. 1950; Lorenz et al. 1952). Furthermore in 1960, it 
was shown that following irradiation; the spleen was able to host the outgrowth of 
macroscopic colonies after being injected with bone marrow cells (Till and McCulloch 
1961; Wu et al. 1967). In fact, the CFU-S assay became one of the first ways to quantify 
hematopoietic progenitors in a clonal manner (Becker et al. 1963).  
Within the CFU-S assay, the kinetics of observable colonies imparts information as to the 
primitiveness of the colony’s founding cell. In combination with the ability to dissect 
these macroscopic colonies and staining for the identity of the cells that constitute the 
colonies, the identity of the progenitor that formed the colony can be ascertained. Quite 
simply, the CFU-S assay operates as an in vivo version of the in vitro CFC assay. Thus, 
after lethally irradiating an appropriate adult mouse, cells are injected into the mouse, 
after which the spleens are examined for the presence of macroscopic colonies (Figure 9). 
Bone marrow progenitors typically give rise to visible nodules on the spleen between 7 
and 14 days after injection, and later colonies were not derived from earlier colonies 
(Magli et al. 1982). This finding allowed for the classification of 8-day spleen colonies 
(CFU-S8) and 12-day spleen colonies (CFU-S12), as discreet populations. CFU-S8 
colonies are generated from oligolineage progenitors; mainly composed of the erythroid 
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lineage, arising from MEPs (Humphries et al. 1979; Magli et al. 1982; Spangrude et al. 
1988). CFU-S12 colonies result equally from the more primitive lineage-committed 
progenitors or MPPs/HSCs (Spangrude et al. 1988; Morrison and Weissman 1994; Magli 
et al. 1982; Nakorn et al. 2002). A third class of spleen colonies known as “pre-CFU-S” 
encapsulates the small population of CFU-S12 colonies that, when injected into a second 
mouse, were able to again generate CFU-S12, indicating self-renew properties, and most 
likely arising from HSCs (Spangrude and Johnson 1990; Ploemacher and Brons 1989; 




Figure 9. A mouse spleen displaying spleen colonies. The mouse was lethally irradiated prior to introduction of 
8x104 bone marrow cells via intravenous injection. Twelve days after injection, spleen was removed and fixed Bouin’s 
solution. Note the prominent, macroscopic colonies that are noticeably lighter in color than the rest of the splenic 




1.6.2. REPOPULATION ASSAY  
Ultimately, the gold standard in assaying for the HSC lies in the ability to reconstitute the 
hematopoietic system in a lethally irradiated adult mouse in a long-term and multilineage 
manner (Bhattacharya et al. 2008; Harrison 1980; Harrison et al. 1993; Kondo et al. 
2002; Orkin and Zon 2008; Avagyan et al.  2010). This assay not only tests the cells 
ability to fully differentiate into all the mature lineages comprising the hematopoietic 
system, but also assesses the ability of the cells to home into the bone marrow niche for 
engraftment and proliferation to reconstitute the hematopoietic system. The power of this 
assay is such that even the rare bone marrow-derived HSC were quantified through the 
combined use of limiting dilutions and long-term repopulation assay (Jones et al. 1996; 
Spangrude et al. 1995; Osawa et al. 1996; Krause et al. 2001). Moreover, the difference 
in self-renewal capacity between the ST-HSC and LT-HSC can only be seen, through the 
use of in vivo repopulating transplants (Jones et al. 1990; Spangrude et al. 1995; Avagyan 
et al. 2010) as current in vitro assays are unable to detect this characteristic.  
The common assumption is that in order to engraft HSCs need “space” to be created 
within the BM niche, as there are limited available physical sites in a steady state BM 
(Bhattacharya et al. 2006; Bhattacharya et al. 2008). “Space” needs to be created within 
the mature cell compartment as well (PB), as HSCs have been shown to preferentially 
repopulate lineages where the demand is highest (Bhattacharya et al. 2006; Lemischka 
1991; Lemischka et al. 1986). Therefore total body irradiation is most commonly used to 
prepare recipient mice at most 24 hours before introduction of hematopoietic cells.  
Examination of PB for multilineage contribution helps to determine the primitiveness of 
progenitors when assessed at specific time points. Typical time points for analysis are at 
8 and 16 weeks post transplant (w.p.t.). At 8-12w.p.t., contribution to PB is mainly due to 
! ! !!45!
the ST-HSCs (Christensen and Weissman 2001). However, only LT-HSCs are able to 
contribute to PB at 16 weeks or longer after transplantation (Christensen and Weissman 
2001). Therefore, one way LT-HSC identity can be determined is by inspection for 
multilineage contribution beginning at least 16w.p.t. (Challen et al. 2008). 
In order to detect donor cell contribution to the mouse after transplantation, two 
approaches can be made. Donor cells inherently expressing a fluorescent molecule may 
be used to detect contribution to hematopoietic tissues, as long as fluorescence expression 
is either ubiquitous and constitutive (Muzumdar et al. 2007), or under control of a 
hematopoietic promoter (Lorsbach et al. 2004). Examining the donor fraction for 
recognition by lineage marker antibodies can assess mature lineage contribution.  
Alternatively the use of CD45.1/CD45.2 isoforms may be used to distinguish between 
host and donor circulating hematopoietic cells (Shen et al. 1986; Spangrude et al. 1988). 
When using CD45 isoforms to detect contribution, the C57BL/6 inbred mouse strain is 
commonly selected as the recipient animal. This inbred mouse strain expresses either 
CD45.1 or CD45.2 on all hematopoietic cells, apart from mature erythrocytes and 
committed erythroid progenitors (Shiku et al. 1975; Thomas 1989; Avagyan et al. 2010). 
Consequently, by injecting cells expressing the opposing isoform to the host, followed by 
a simple staining with antibodies recognizing each isoform, the percentage of 
contribution by donor cells can be determined. By combining CD45 isoform staining 
with the previously discussed staining for lineage markers, it is possible to further 




1.7. EXPERIMENTAL HYPOTHESIS AND APPROACH 
The etiologies of some chronic human diseases lie in the specific deficiency of a 
particular cell type as reviewed by (Murry and Keller 2008), and thus such diseases 
should be stably treatable by direct replacement of the missing cell type—a “cell 
replacement” therapy. Consequently, a key question is how to generate these cell 
populations for therapeutic replacement. One such system that can benefit from this kind 
of cell replacement is the hematopoietic system. For example, leukemia, a cancer 
characterized by inappropriate differentiation of blood progenitors, is addressed by the 
treatment of cancerous progenitors through chemotherapy, or complete replacement of 
existing bone marrow. In practice today is autologous, or donor derived bone marrow 
transplantation, in which bone marrow is harvested and the residing HSCs are expanded 
in vitro before being re-introduced to the recipient system. While this process possesses 
limited success as a therapy for leukemia, it is still a fairly inefficient process, due in 
large part to the scarcity of HSCs within the adult bone marrow compartment, and current 
limitations in expansion procedure. Therefore, we aim to provide an alternative option 
utilizing the revolutionary process of reprogramming terminally differentiated cells 
directly into a specific somatic stem cell.  
The hematopoietic system is one of the best-characterized systems in both mouse and 
humans. Given the success of generating iPS from MEF, we sought to employ the 
knowledge gleaned from decades of work in the hematopoietic system to address the key 
question of direct differentiation to a somatic stem cell, specifically the HSC. We 
hypothesized that overexpression of the right combination of hematopoietic specific 
transcription factors, and a culture technique that mimicked the bone marrow niche, could 
directly induce the hematopoietic program in a terminally differentiated cell. 
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To accomplish this task, we approached it in a fairly sequential manner. First we 
attempted to induce the hematopoietic state in an easily manipulated background, 
specifically p53-/- fibroblasts (Hong et al. 2009; Kawamura et al. 2009; Li et al. 2009; 
Marión et al. 2009; Utikal et al. 2009a). From various reprogramming experiments, we 
know that the target cell is as crucial to the success of this enterprise as the end state. 
Previous studies have shown the importance of cell cycling in determining the attainment 
of the iPS state (Yamanaka 2007; Zhao et al. 2008; Tapia and Scholer 2010). The rare 
occurrence of a successful reprogramming from MEF to iPS is enhanced by the 
utilization of a p53 deficient MEF as a starting point. Akin to iPS reprograming, we 
expected that the generation of an induced hematopoietic stem cell (iHSC) would also be 
a rare event; therefore we began by first targeting MEF derived from p53-/- mice. 
To determine the transcription factors necessary to induce the iHSC state, we started with 
a panel of 6 factors, all of which have been shown to be involved in the derivation or 
proliferation of the HSC – Scl, Lmo2, Hoxb4, Gata2, Gfi1, and Bmi1. These factors were 
consequently overexpressed through viral infection, and analysis was performed across 
the panel of assays described earlier. It became evident in the course of our study that all 
6 factors were not necessary to induce the hematopoietic state, resulting in the elucidation 
of a 4-factor combination crucial to inducing hematopoietic characteristics.  
As a proof of concept, the same induction protocol was conducted with wild-type (WT) 
MEF to ensure that any reprogramming event was not an artifact of the p53-/- 
background. Analysis was again done as described. 
Ultimately, once in vitro assays had shown proof of induced hematopoiesis, the next 
challenge was to test for true hematopoietic identity under biological conditions. We 
therefore transplanted various prospective iHSC populations into the NOD/SCID 
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interleukin 2 receptor (IL2R) gamma null (NSG) mouse strain, expressing CD45.1 
isoform. This mouse strain exhibits both severe combined immune deficiency as well as 
IL2R γ-chain deficiency. These two deficiencies result in a model with an absence of 
mature B and T cells, as well as a lack of functional NK cells, due to a deficit in cytokine 
signaling. One advantage conferred by using an immune deficient mouse lay in the ease 
of identifying any in vivo lymphoid potential of our induced hematopoietic progenitors. 
However, due to the vulnerability of the NSG’s severe immune deficit, we also employed 
wild-type mice in our in vivo assays once a reliable reporter line was found.  
By utilizing a ubiquitously expressed red, Dsred-fluorescent marker in the widely 
expressed Rosa26 locus, mouse reporter line (Muzumdar et al. 2007), to generate target 
MEFs (Dsred-MEF), we were able to efficiently track our reprogramming under wild 
type conditions. A crucial aspect of these target cells was their reliable and continuous 
fluorescence in all cell types, throughout all stages of differentiation, from stem to mature 
cell (Muzumdar et al. 2007). This allowed us to both test our ability to reprogram cells in 
a wild-type target cell, as well as to assay our reprogrammed cells under optimal 
biological conditions.  
A summary of our experimental set up can be seen in Figure 10, indicating the intervals 




Figure 10. Summary of experimental approach. Adherent MEF was infected with retrovirus containing pMX vectors 
carrying select TFs. At 4d.p.i., stromal cell line OP9 was introduced to the culture, and hematopoietic cytokines were 
added to the media. This co-culture was continued until cobblestone colonies, and suspension cells were observed. At 
this point, suspension cells were harvested and assayed using surface marker staining analysis by FACS, placed into 



















2.1 CELL CULTURE 
2.1.1. CULTURE OF OP9 STROMAL CELLS 
OP9 stromal cells (generously given to us by Dr. Tara Huber) were expanded and 
maintained in IMDM (Gibco) containing 20% FBS (heat inactivated at 56°C for 30min), 
1% penicillin/streptomycin (Gibco), and 100μM monothioglycerol (MTG, Sigma-
Aldrich), at 37°C under 5% CO2 atmosphere. Cells were passaged when cultures reached 
~70% confluency using the following process: Media was aspirated and cells were 
washed once with 1xPBS solution (Gibco). Cultures were then incubated at room 
temperature (RT) with 0.25% Trypsin-EDTA (Gibco) until cells began to detach from the 
culture surface. Culture surfaces were washed with equal volume of culture media, and 
detached cells were harvested and pelleted in a centrifuge at 3min/300 x g. The pellet was 
titrated with fresh media to achieve a single-cell suspension and plates were seeded at a 
ratio of 1:20 onto new gelatin-coated plates. 
Inactivation of OP9 cells was done by mitomycin-c treatment.  
2.1.2. CULTURE OF MURINE EMBRYONIC FIBROBLAST (MEF) 
Runx1-IRES-GFP-MEFs were generously provided by Dr. Motomi Osato of Cancer 
Science Institue of Singapore. p53-/-MEFs were received from a colleague in lab.  
Dsred-MEF was generated from embryonic day 13.5 embryos attained from homozygous 
mating of R26TG mice (Jackson Lab) using the following protocol: Embryos were 
harvested from both uterine horns and cleared of placenta and amniotic sac in 1xPBS. 
The head and any red tissues in the body cavity was removed using sharp forceps. The 
remainder of the embryos were minced with sharp scissors, then transferred into 0.25% 
Trypsin-EDTA and titrated to generate smaller pieces. This was then incubated at 37°C 
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for up to 30mins before being titrated again to further break up tissue chunks and get cells 
into suspension. Equal volume of MEF media was added, and the tissue and cell 
suspension was pelleted at 3min/300 x g. Supernatant was aspirated. The pellet was 
resuspended in MEF media and plated on to cell-culture treated plates labeled as passage 
0. Media was changed every 24 hours. Once cultures had reached ~70-80%, cells were 
harvested and stained for lineage depletion through FACS sorting, as described below, 
before use as target cells or cryopreserved for future use. All antibodies used for flow 
cytometric analysis were used to deplete MEFs of any potential hematopoietic 
contamination.  
MEFs were maintained in DMEM containing 10% heat-inactivated FBS, 1% 
penicillin/streptomycin, and 1% L-Glutamine (Gibco), at 37°C under 5% CO2 
atmosphere. Cultures were passaged at ~70% confluency using the same method as 
described above. Fibroblast cells were split at a ratio of 1:4 and plated directly onto cell-
culture treated plates.  
2.1.3. CULTURE OF PLATINUM-E CELLS (PLAT-E) 
PLAT-E cell (Cell Biolabs) were maintained in DMEM with 10% heat inactivated FBS, 
1% penicillin/streptomycin, 1μg/ml puromycin and 10μg/ml blasticidin, at 37°C under 
5% CO2 atmospheres. Cultures were passaged when cells reached ~70% confluency as 
per OP9 cells. Cells were split at a ratio of 1:5 during expansion.  
2.1.4. CULTURE OF IHPS 
At 3-5 days post-infection of MEF, inactivated OP9 was seeded onto the plate, at a 
concentration of 1.5x106 cells per 10cm plate, in IMDM (Gibco) with 15% heat 
inactivated FBS, 1% penicillin/streptomycin and 100μM MTG. Two days after the 
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addition of inactivated OP9, a full change of media was made, at the same time, the 
following cytokines were added; 10μg/ml rmSCF, 10μg/ml rmFLT-3L, 10μg/ml rmIL-3, 
and 5μg/ml rmTPO (all from R&D Systems). Successive media changes occurred every 
2-3 days in which only half the volume was replaced by fresh cytokine supplemented 
media.  
2.1.5. CRYOPRESERVATION OF CELL LINES 
All cell lines were cryopreserved using the following procedure: Confluent cultures of 
cells were trypsinized as described for OP9 cells. Cells were pelleted at 5min/300 x g. 
Pellets were resuspended in freezing media, comprised of 70% DMEM with 20% FCS 
and 10% dimethyl sulphoxide (DMSO), and transferred into Nunc cryotubes. Cryotubes 
were placed in -80°C overnight in Nalgene® Mr Frosty containers buffered with 
isopropanol and then transferred into liquid nitrogen tanks the following day for long-
term storage.  
2.1.6. THAWING OF CELL LINES 
All cell lines were thawed using the following procedure: Frozen cryotubes were 
retrieved from liquid nitrogen takes and immediately placed into a 37°C water bath. Cells 
were rapidly thawed and transferred into 10ml of pre-warmed culture media. The cell 
suspension was then pelleted at 3min/300 x g. Pellets were resuspended in culture media 
and plated onto cell culture dishes overnight to allow for cell adhesion to the culture 
surface before media was changed.  
2.1.7. RETROVIRAL PRODUCTION AND INFECTION OF MEF 
All TFs used were cloned into the pMXs vector (Cell BioLab) by a colleague in our lab.   
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PLAT-E were seeded at about 8x106 cells per T75 flask and incubated overnight in 
PLAT-E culture media without the addition of puromycin or blasticidin. Next day PLAT-
E cultures were transfected with pMXs vectors using 16μg of each vector and Fugene 6 
transfection reagent (Roche) at a ratio of 1:3. For each vector Fugene 6 was first 
incubated in 500μl, per flask, of OptiMEM for 5min, before the addition of the pMXs 
vector and a further 20min incubation at RT. This solution of transfection reagent and 
pMX vector was added directly into PLAT-E cultures in fresh, antibiotic–free, media, at 
37°C under 5% CO2 atmosphere. 
Media was collected after 48hrs and filtered through a 0.45μm!filter!to!remove!cellular!debris.! Filtered! retroviral! supernatant!was! then! concentrated! using! Amicon! Ultra!spin!columns!(Millipore)!as!per!manufacturer’s! instructions.! Infection!was!done! in!MEF!media!with!the!addition!of!8μg/ml!of!polybrene.!Equal!amounts!of!each!virus!was!mixed,!placed!onto!MEF!culture,! and! incubated!overnight.!Concentrated!virus!was! introduced!to!p53O/OMEFs,!plated!the!day!before!at!200K!cells/10cm!plate,!or!DsredOMEF,! plated! the! day! before! at! 400K! cells/10cm! plate.! The! next! day! viral!containing!media!was! removed! and! replaced!with! fresh!MEF!media! and! cultured!overnight!before!the! introduction!of! inactivated!OP9.!Plates!were!then!maintained!as!described!in!culturing!iHPs.! 
2.2. MOUSE TECHNIQUES 
2.2.1. MOUSE STRAINS 
Congenic knock-in R26TG mouse strain from Jackson Lab (stock no. 007676) was 
maintained for MEF generation. Inbred C57BL/6 and NSG, congenic with SzJ, (Jackson 
Lab, stock no. 005557) mouse strains were used as hosts in in vivo assays at 6-10weeks 
! ! !!55!
of age. All mouse techniques were performed in accordance with approved IACUC 
protocols. 
2.2.2. IRRADIATION OF HOST ANIMALS 
Mice were fed filtered acid water (pH 4.2, using 0.1N HCl in sterile H2O) for one week 
prior to irradiation, and for the duration of the experiment. Irradiation was conducted 
using a gamma irradiator at either 7Gy for C57BL/6, or 300Gy for NSG strains. 
Irradiation was conducted 24hrs before use.  
2.2.3. INTRAVENOUS TAIL VEIN INJECTION (IV) 
Donor cells were counted and resuspended in IMDM basal media prior to injection. Host 
mice were initially warmed under a heat lamp for 5mins to encourage blood flow to the 
tail veins. The mouse was then placed into a mouse restrainer that allows access to the 
tail vein. 100-200μl of cell solution was loaded into a 1μl syringe with a 27G needle, with 
care being taken to clear all air bubbles from the syringe and needle. The needle was 
inserted into the tail vein, bevel up, and the cell solution was injected with a fluid motion. 
Correct placement of the needle was confirmed by checking for tail vein blanching as the 
cell solution was being injected.  
2.2.4. INTRAPERITONEAL INJECTION (IP) 
Mice were individually restrained by the scruff of the neck, as well as securing the tail, 
exposing the ventral side of the animal. A prepared syringe is placed, bevel up, in the 
lower right or left quadrant of the abdomen while the head is tilted at a downward angle. 
The needle is inserted at a 30° angle, and the plunger is depressed in a fluid motion. 
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2.2.5. INTRACARDIAC PUNCTURE  
When more than 100μl of blood was required, or when the mouse was to be sacrificed for 
organ harvesting, cardiac puncture was used.  Mice were weighed and anesthetized by IP 
injection of Ketamine (150mg/kg) + Xylazine (10mg/kg). The mouse was checked for 
lack of pain response by pinching the rear foot before continuing. The mouse was laid on 
its back and each paw is secured out-stretched to expose the ventral side. A 25G needle is 
placed just below the xiphoid cartilage and slightly left of the middle. The needle is 
introduced at a 10-30° angle from the horizontal as it approaches the heart. Entrance into 
the heart is gained once blood is seen to enter the syringe. Blood is aspirated from the 
heart by slowly pulling back on the plunger and allowing blood to fill the vacuum. On 
average, 0.6-0.8ml of blood was collected. Collected blood was placed into equal 
volumes of blood collection buffer (BCB, DMEM, 5% heat-inactivated FBS, 0.5mg/ml 
porcine heparin [Sigma]). Once the intra-cardiac puncture was complete, mice were 
euthanized by cervical dislocation.  
2.2.6. RETRO-ORBITAL BLEEDING 
Mice were anesthetized through inhalation of 3% isoflurane in 100% oxygen. The mouse 
was completely under anesthesia as measured by lack of rear foot reflexes before 
beginning. A heparinized microhematocrit capillary tube (Fisher Scientific) is placed at 
the inner corner of the eye and punctures the conjunctiva using a rotating motion. Once 
blood begins entering the capillary tube through capillary action, the tube is held still 
until blood fills the tube. ~140μl of blood is collected per mouse, per bleed. When the 
desired amount of blood has been collected, the tube is removed and slight pressure is 
applied to the eye by gauze to prevent further bleeding. Collected blood was placed into 
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an equal volume of BCB. Blood collection using this method was conducted once every 
two weeks.  
2.2.7. HEMATOPOIETIC ORGAN HARVEST 
After mice were euthanized following intracardiac bleeding, spleen and both femurs were 
removed. Spleen was removed from the abdominal cavity whole and placed directly into 
enough 1xPBS containing 2% FBS, to completely cover the organ. Femurs were removed 
at the hip and knee joints. Muscle and connective tissues were cleaned off the bones prior 
to being placed in enough 1xPBS with 2% FBS, to completely cover the bone, before 
processing for further assays.  
2.3. FLOW CYTOMETRY AND CELL SORTING 
2.3.1. RBC LYSIS AND SINGLE CELL SUSPENSION PREPARATION OF BONE MARROW AND SPLEEN 
Femurs were cleared of bone marrow by first cutting both ends of the bone. A 27G 
needle and syringe containing 5% FBS supplemented IMDM was used to flush bone 
marrow out of the bone. The same syringe was used to break up any remaining clumps by 
passing the solution through a 22G needle until a single cells suspension is seen.  
Spleens were homogenized between the frosted ends of two slides. The resulting slurry 
was passed through a 70µm cell strainer using the same media as mentioned above.  
Both homogenized bone marrow and spleen were centrifuged at 7-10min/350 x g. Red 
blood cells (RBC) were removed using 1-2ml of RBC lysis buffer (Sigma) at RT for 
5min. 1xPBS was used to dilute the buffer before pelleting. If the pellet is still red, lysis 
was repeated. Pellets were resuspended in FACs staining buffer (1xPBS, 0.2% Bovine 
Serum Albumin [Sigma-Aldrich], 2% FBS) and passed through a 30µm mesh to obtain a 
single cell suspension.  
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All single cells suspensions were processed using pre-chilled buffers, and kept on ice to 
prevent epitope capping, unless otherwise stated.  
2.3.2. RBC LYSIS OF PERIPHERAL BLOOD 
RBC removal from PB samples harvested from retro-orbital or intracardiac bleeding was 
done using ammonium chloride lysis buffer (ACK). 10xACK lysis buffer (1.5M NH4Cl, 
100mM KHCO3, 1mM EDTA, in ddH2O) was diluted to 1xACK by ddH2O, prior to the 
addition of whole PB. Approximately 10ml of 1xACK was used per 1ml of whole blood. 
Lysis occurred at RT with continuous agitation for no more than 10mins. An equal 
volume of 1xPBS was used to dilute the lysis solution prior to pelleting at 8min/350 x g. 
If the pellet was still red, lysis was repeated. Pellets were resuspended in FACs staining 
buffer as described above and passed through a 30µm mesh to obtain a single cell 
suspension.  
All single cells suspensions were processed using pre-chilled buffers, and kept on ice to 
prevent epitope capping, unless otherwise stated.  
2.3.3. STAINING PROCEDURE FOR FACS ANALYSIS AND SORTING. 
Fcγ-receptors of single cell suspensions prepared from PB, bone marrow, or spleen were 
blocked by 20min incubation, on ice, with unlabeled anti-CD16/CD32 (2.4G2) antibody 
(BD Bioscience), before staining with fluorescently labeled antibodies. Antibodies to the 
following antigens were used: CD3ε (145-2C11), CD4 (L3T4), CD8α (53-6.7), Gr-1 
(RB6-8C5), CD11b (M1/70), CD19 (MB19-1), CD41 (MWReg30), CD61 (C29.G3), 
CD71 (R17217), CD45R/B220 (RA3-6B2), CD45 (30-F11), CD45.1 (A20), CD45.2 
(104), CD48 (HM48-1), CD117/c-Kit (2B8), CD150 (9D1), Sca-1/Ly6A/E (D7), Ter119 
(Ter-119), directly conjugated to FITC, PE, APC, or eFluor®450 in the combinations 
specified in Table 1. As mentioned in MEF preparation, all antibodies listed were used in 
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sorting out any hematopoietic cells, before use as target cells. All antibodies were from 
BD Biosciences or eBioscience and were used at manufacturer recommended 
concentrations. Cells were incubated with antibody for 30min at 4°C before washing. 
Labeled cells were washed twice using staining buffer and centrifuged at 5min/300g. The 
pellet was resuspended in staining buffer before data acquisition using LSR II (BD 
Biosciences) or FACSAria (BD Biosciences), with dead cells being excluded based on 
scatter profile. Analysis was preformed on FACS Diva (BD Biosciences) software; 
through which live cells were examined for expression of identifying surface markers via 
detection of fluorescence signals. Sorted cells were collected in DMEM containing 5% 
FBS and 40µg/ml Gentamicin. Sorting was done using a MoFlo (Dako North America) or 
FACSAria (BD Biosciences).  
2.4. IN VITRO ASSAYS 
2.4.1. COLONY FORMING CELL ASSAY 
Semi-solid media was prepared using Methocult® M3234 (StemCell Tech) with the 
addition of the following recombinant cytokines: 100ng/ml rmSCF, 100ng/ml rmIL-3, 
10ng/ml rmGM-CSF, 5ng/ml IL-11, 4U/ml rmEPO, 10ng/ml IL-6, 50ng/ml rmTPO. A 
16G needle and syringe was used to measure and aliquot volumes of Methocult® 
medium, by first drawing Methocult® into the syringe and expelling it completely to 
remove any air. Test cells were prepared by initially being washed with IMDM to remove 
any traces of culture serum. Cells were counted and resuspended in 0.4ml of IMDM that 
when added to 4ml of complete Methocult® media, resulted in 50,000 or 10,000 cells per 
ml. Once cells were added to semi-solid media, it was thoroughly mixed by vortexing. A 
16G needle and syringe was used to aliquot 1.1ml into 35mm petri dishes. Tilting and 
rotating each dish achieved even distribution of methylcellulose. Cultures were placed 
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into a 150mm petri dish with an additional uncovered 35mm dish containing 5ml of 
sterile H20 to prevent dehydration, and kept at 37°C under 5% CO2 atmosphere. Each test 
was conducted in triplicate.  
Colonies were evaluated and classified by colony morphology at 2-days (CFU-E) and 15-
days (all other myeloid colonies) after plating. An inverted microscope was used to 
visualize and image any myeloid colonies. Individual colonies were picked, for further 
analysis by Wright-Giemsa or benzidine staining, using a 200µl pipette and placed into a 
1:10 by volume ratio of methylcellulose to PBS containing 2% FBS. The tip was rinsed 
thoroughly in this buffer to ensure minimal cell loss. 
2.4.2. CYTOSPIN AND STAINING BY WRIGHT-GIEMSA OR BENZIDINE 
Cytospin slides were prepared from suspension cells direct from culture or from 
individual colonies picked from CFC assay, for identification by nuclear morphology. 
Cells were counted and diluted to 5x105cells/ml in PBS. 100ul of cell solution was loaded 
into a double chambered cytofunnel and slide (Thermo Scientific). The assembly was 
loaded and spun at 3-5min/700rpm, in a Shandon Cytospin 4 (Thermo Scientific). Slides 
were removed from the assembly and allowed to air dry for 5min before being fixed in 
methanol at -20°C for 3min.  
Once slides were dry, Wright-Giemsa staining was conducted to visualize nuclear 
morphology. Stock Wright-Giemsa (Sigma-Aldrich) was diluted 1:20 using distilled 
water, and added drop-wise to the slide ensuring full coverage of the area to be stained. 
After incubating at RT for 20mins, slides were washed twice with 1xPBS and once with 
water. Slides were allowed to air-dry overnight before being mounted with a coverslip.  
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Benzidine (DAB, Sigma-Aldrich) staining to visualize the presence of hemoglobin was 
performed as follows: prior to staining, a benzidine tablet was dissolved in 15ml 1xPBS 
and filtered through a 0.22µm syringe mounted filter. Immediately before using, 12ul 
30% hydrogen peroxide solution was added. Prepared benzidine was added drop-wise on 
dry slides, covered and incubated at RT for 1-2hrs. Slides were washed 2-3 times with 
1xPBS before being counterstained with Wright-Giemsa as described above.  
All stained slides were imaged using a Leica DM LB2 (Leica Microsystems). 
2.5. IN VIVO ASSAYS 
2.5.1. SPLEEN COLONY FORMING ASSAY 
Wild-type C57BL/6 mice, at 6-10 weeks old, were irradiated at 7Gy in the manner 
described above. Test cells were IV injected at 5x106 or 1x106 cells in 200ul of IMDM, 
no more than 24hrs after irradiation. Mice were continuously fed acid water for the 
duration of the trial. Fourteen days after injection, mice were sacrificed; peripheral blood, 
bone marrow and spleen were harvested. Whole spleens were imaged using a Leica 
M205 FA (Leica Microsystems), and a UV light source for fluorescence, immediately 
prior to homogenizing for flow cytometry. Peripheral blood and bone marrow were 
immediately processed in preparation for flow cytometry in the manner described 
previously.  
2.5.2. REPOPULATION ASSAY 
NSG mice, at 6-10 weeks old, were irradiated at 5.5Gy in the manner described. Test 
cells were IV injected at 5x106 or 1x106 cells in 200ul of IMDM, no more than 24hrs 
after irradiation. Retro-orbital bleeding procedure was employed to harvest peripheral 
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blood for assessment of donor cell contribution, at 2 week intervals, by flow cytometry as 



















In order to assess if we were progressing in the right direction, we first combined all the 
transcription factors we thought important for the hematopoietic lineage and over 
expressed them in fibroblasts in which expression of green fluorescent protein (GFP) is 
controlled by the Runx1 promoter (Runx1-GFP; Lorsbach et al. 2004). As Lorsbach and 
lab reported in 2004, the knock-in mouse strain did not show any phenotypic 
abnormalities in reproductive success or within the hematopoietic compartment, when 
compared to wild-type mice, indicating the normal function of Runx1. More notably, 
Runx1 directed GFP expression was seen in almost all progenitors cells expressing c-Kit, 
correlating nicely with the known importance of Runx1 in hematopoiesis. We therefore 
utilized MEF derived from the Runx1-GFP mouse (Runx1-GFP-MEF), as a target cell, to 
quickly assess entry into the hematopoietic system.  
However, as discussed before, reprogramming is a fairly inefficient and slow process. 
Thus to speed things up, we also employed the over expression of two known oncogenes, 
c-Myc and SV40LT (together, “MT”). These oncogenes were employed in parallel with 
overexpression of 6 hematopoietic transcription factors (6F), as reviewed by Orkin and 
Zon in 2008. We hoped, with the addition of MT, to increase the efficiency and kinetics 
of iHP as they have been shown to do in pluripotent reprogramming (Nakagawa et al. 
2008; Park et al. 2008). 
As we were unsure of what to expect from this novel approach, we utilized standard 
assays. First, knowing that the hematopoietic lineage has a rather unique characteristic of 
generating suspension viable cells in vitro, we looked for any gross morphological 
changes leading to the emergence of adhesion independent cells. Secondly, knowing the 
extensive work done that has identified combinations of cell surface markers recognizing 
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not only the HSC and mature cells, but their intermediate progenitors as well allowed us 
another means through which to examine the success of our reprogramming. To further 
gauge any possible progenitor potential generated we employed the CFC assay. As this 
was quite an exploratory study, we did not deem in vivo assays a necessity, at least until 




3.2.1. IN VITRO MORPHOLOGICAL CHANGES 
Morphological changes were evident as early as 6 days post-infection (d.p.i.; Figure 11). 
At 18d.p.i, numerous semi-adherent cells emerged from the fibroblast monolayer. These 
semi-adherent cells were capable of remaining viable in suspension, exhibiting a 
recognized characteristic of hematopoietic cells. Moreover, these cells also showed 




Figure 11. Runx1-GFP-MEF 6 days post-infection. A) uninfected MEFs showing normal fibroblast morphology 
(40x); B) loose clusters of small, rounded less refractile cells can be seen in MT infected MEFs (40x); C) Tight clusters 
of small, rounded less refractile cells are mixed with highly refractile, semi-adherent cells are seen in MEFs infected 





3.2.2. SURFACE MARKER CHARACTERIZATION BY FACS ANALYSIS 
In order to ensure our suspension viable cells were in fact of hematopoietic identity, we 
endeavored to identify them by surface markers characteristic of the hematopoietic 
system. There were two discrete populations found indicative of the myeloid lineage. 
Specifically, a population of CD71+/Ter119+ co-positive cells signifying immature 
erythrocytes (Zhang et al. 2003a), and a CD41+/CD61+ co-positive population marking 
megakaryocytes (Phillips et al. 1988). 
When this population was stained for other surface markers characteristic of the other 
mature lineages, we were disappointed. For example, there was a distinct lack of 
evidence of CD11b+/CD45+ cells characteristic of mature macrophage. Likewise, there 
was also a lack of Gr-1+/CD45+ cells, classically recognized as mature granulocytes. 
However, while the double positive cells were not found, there was a significant 
population of CD11b+/CD45- cells found in suspension. Moreover, using combinations of 
markers to identify lymphoid lineages, CD3/4/8 for the T cell branch, and B220/CD19 
for B cells, also showed an absence in our population of suspension viable cells. 
 
3.2.3. IN VITRO CFC ASSAY 
We sampled the culture at 5d.p.i. and placed suspension cells into the colony assay to 
assess differentiation potential. Amazingly, by 5d.p.i., infected fibroblasts differentiated 
into small red colonies comprised of benzidine-positive erythroid cells (not shown). We 
also observed megakaryocyte colonies that were acetylcholine positive (not shown). 




Initial results from overexpression of our 6 candidate transcriptions factors we believed to 
be critical for hematopoietic lineage identity proved promising. By utilizing 
hematopoietic lineage specific cell surface markers, as well as a cell line with 
hematopoietic specific reporter (Runx1-GFP-MEF), we were able to ascertain that 
overexpression of these 6 transcription factor in combination with two oncogenes (MT) 
was able to reprogram MEF into the hematopoietic lineage.  
The generation of suspension viable cells, that at 18d.p.i., identified as mature cells 
within the myeloid lineage, together with the outgrowth of mature colonies in the CFC 
assay collectively lead us to the conclusion that we did indeed enter into the 
hematopoietic lineage. Since at 18d.p.i. suspension cells in culture had identified as fairly 
mature erythrocytic and megakaryocytic cells (Zhang et al. 2003a; Phillips et al. 1988), 
we conducted the CFC assay at an earlier time point. We hypothesized that since the 
hematopoietic system is a fairly dynamic lineage, our mature populations had in fact 
arisen from more primitive progenitors, which had subsequently differentiated into the 
populations we had detected by cell surface staining. The resulting benzidine positive, 
and acetocholinesterase positive colonies arising from 5d.p.i. suspension cells had to have 
arisen from erythroid, and megakaryocyte progenitors as these colonies were comprised 
of only one type of mature cell. The rare colony found to contain both erythroid and 
megakaryocyte indicated a rare bi-potential progenitor; in this case a MEP (Akashi et al. 
2000).  
There was no indication of the other cell types that make up the myeloid lineage, namely 
macrophage and granulocytes. Cell surface marker staining did not identify mature 
populations of CD11b+/CD45+ mature macrophage or Gr-1+/CD45+ granulocytes. 
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However finding abnormal expression of CD11b+/CD45- populations implied that there 
was a problem with the normal maturation process of macrophage cells. Normal 
maturation for the majority of hematopoietic cells involves first the gain of CD45+, then 
progression into the mature hematopoietic lineage markers, CD11b, Gr-1, CD3/4/8, and 
B220/CD19. Mature megakaryocytes and erythrocytes are the exception in their lack of 
CD45 expression, and these are identified with their own marker combinations as 
described above. Thus by seeing a population of CD11b+ cells that were not also CD45+ 
indicates a disruption in the normal progression of macrophage maturation. 
These initial results, when taken together, showed that while there were obvious 
imperfections in our attempt to reprogram MEFs into HSCs, it did indicate that we were 
on the right track. The evidence of hemaglobinized cells, as well as acetylcholinesterase 
positive megakaryocytes showed that the hematopoietic program was being activated in 
transfected MEFs. However, as we were not able to produce evidence of any other 
lineages of the hematopoietic program, nor did we see evidence of more primitive 
hematopoietic progenitors with broader multi-lineage differentiation ability, we 










REPROGRAMMING OF P53-/- MOUSE 








Following on the heels of the provisionally promising results from the use of oncogenes 
and our factors, we reasoned that successful reprogramming into multipotent 
hematopoietic cells might be exceedingly rare. Thus, we postulated increased cell cycling 
would improve the efficiency of such events by enabling clearance of the starting 
fibroblast epigenetic program and facilitating induction of a new hematopoietic 
transcriptional program (Egli et al. 2008). However, the previous strategy of utilizing two 
powerful oncogenes, c-Myc and SV40LT, to drive cell cycle resulted in reprogrammed 
cells of fairly mature hematopoietic identity. This may be due to the fact that 
overexpression of c-Myc can direct HSCs out of the stem cell niche and down the 
differentiation pathway, mainly by disrupting the cell-to-cell interaction between HSCs 
and their bone marrow niche (Wilson et al. 2004). More specifically, the overexpression 
of c-Myc enhances proliferation of megakaryocytes at the occasional cost of nuclear 
polyploidy (Thompson et al. 1996). Ultimately, overexpression of c-Myc does disturb 
normal HSC homeostasis as well as its normal differentiation preferences. As our goal is 
to reprogram into not only the hematopoietic program, but specifically into the stem cell 
tier, any disruption to the stem cell self-renewal cycle is detrimental. Therefore, we 
explored other avenues in which cell cycling could be enhanced, without risking the HSC 
state.  
p53-/- mice offered us the potential to increase cell cycling without having to overexpress 
c-Myc. The deletion of the tumor suppressor p53 leads to increased cell cycling and 
proliferation, without any noticeable effect on the hematopoietic system. As the genetic 
ablation of p53 significantly enhances the efficiency and kinetics of pluripotent 
reprogramming (Utikal et al. 2009a), we hoped to harness that same enhanced efficacy by 
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targeting p53-/-MEFs to achieve hematopoietic reprogramming in the absence of c-Myc 
and SV40LT.  
In an effort to ensure we were not merely assessing lingering hematopoietic cells within 
our fibroblast culture, before infecting our target cells with our chosen TFs, we first 
purified our pool of target cells. We used a combination of cell surface markers 
identifying hematopoietic cells from the HSC to mature cells, across all lineages, and 
FACS to sort out any cells marked by this combination. Thus we ensured a non-
hematopoietic starting point.  
Another change included the co-culture of infected fibroblasts with OP9 stromal cells. 
This cell line has been shown to support primitive hematopoietic progenitors in culture 
(Nakano et al. 1994), on media supplemented with hematopoietic cytokines known to 
support HSCs, such as SCF, IL-3, TPO, and FLT3LG (Holyoake et al. 1996; Miller and 
Eaves 2002; Sitnicka et al. 1996). One great advantage to utilizing this co-culture system 
was its similarity to the cobblestone area forming cell assay (Figure 7; Ploemacher et al. 
1991). This allowed us to identify potentially rare, yet successful, reprogramming events 
by morphology at an earlier time point than the onset of suspension viable cells alone. 
Much like the previous approach using Runx1-GFP-MEFs, p53-/-MEFs were transduced 
with our 6 factors, minus MT. Two days after infection, MEFs were replated onto OP9 
stromal cells and treated with hematopoietic cytokine supplemented media. These 
cultures were observed for morphological changes in co-culture. Further assays were 
conducted on suspension cells from these same co-cultures as indicated below.   
Here again we strove to examine any resultant reprogrammed cells through a multi-
pronged approach; namely by observing morphological changes, cell surface marker 
recognition, differentiation potential, as well as in vivo transplantations. Through the use 
! ! !!74!
of these diverse assays we hope to be able to shed light on what class of cell within the 




4.2.1. IN VITRO MORPHOLOGICAL CHANGES AND CAFC 
As early as 8d.p.i. almost all MEFs lost characteristic mesenchymal fibroblast 
morphology, and numerous foci of tightly clustered cells appeared. By 9d.p.i., suspension 
cells emerged from culture. In comparison, the suspension cells were not as numerous as 
those previously seen in the 6F+MT combination.  
As these cultures were allowed to continue, beginning at 20d.p.i. adherent cobblestone 
colonies began to emerge (Figure 12). These colonies showed morphology highly 
evocative of those formed by authentic hematopoietic progenitors in vitro (Figure 7; 
Ploemacher et al. 1991).  
Cobblestone colonies (Figure 12) derived from 6F-p53-/-MEF were identified by at least 8 
less refractile, tightly packed cells whose individual morphology is reminiscent of paving 
cobblestones. These colonies were often interspersed with bright, highly refractile semi-
adherent cells believed to be more differentiated hematopoietic cells being expelled into 
suspension. Suspension cells thus having originated from these progenitor containing 
cobblestone colonies (Nakano et al. 1994; Ploemacher et al. 1991). Once cobblestone 





Figure 12. 6F-p53-/-MEF cobblestone colonies. 25 d.p.i., on OP9 stromal cell feeder, exhibiting colonies of tightly 
packed, less refractile cells accompanied with bright, highly refractive semi-adherent cell; long and stringy MEF and 
OP9 cells can be seen in the background of the middle and right panel; Left panel at 100x, middle and right panels at 




4.2.2. SURFACE MARKER CHARACTERIZATION BY FACS ANALYSIS  
To characterize hematopoietic surface marker expression, FACS analysis was used on 
suspension cells from 6F-p53-/-MEF on OP9 co-culture. 9d.p.i. cells found a modest 
population staining positive for CD41 (Figure 13). This marks both myeloid cells 
(Phillips et al. 1988) as well as nascent HSCs that arise during the earliest phase of fetal 
hematopoiesis (Ferkowicz et al. 2003). At this early time point however, no other 
hematopoietic markers were seen including the mature pan-hematopoietic cell marker 
CD45.  
When FACS analysis was conducted on suspension cells after the appearance of 
cobblestone colonies, we found evidence of more mature hematopoietic surface markers. 
When suspension cells were stained for mature lineage markers at 30d.p.i. (Figure 14) we 
found a 10% population staining positive for CD45 that was also recognized by CD11b, a 
mature lineage marker indicative of macrophages. Furthermore, FACS analysis revealed 
a 70% population of Gr-1 positive cells, marking granulocytes. When suspension cells 
were examined for CD41/CD61 double positive cells, indicative of megakaryocytes, and 
found a small 2% population. Meanwhile, within the erythrocyte lineage, we found 
another large population of 70% CD71 positive cells, and small populations of 
approximately 1% Ter119 positive cells, 0.7% of which was also CD71/Ter119 double 
positive. While Ter119 positive cells encompassed only a small percentage of the total 
cells, the separation and distinct grouping of the signaling makes for convincing evidence 
of a population of mature erythroid cells. Taken together at 30d.p.i, according to cell 
surface markers, suspension cells contain both mature and maturing hematopoietic cells 
within the myeloid lineage. Moreover, we could not visualize any evidence of lymphoid 
makers.   
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Figure 13. FACS dot plot of 9 d.p.i. 6F-p53-/-MEF suspension cells as stained by CD41, revealing a 47% population 





Figure 14. FACS dot plots of 30 d.p.i. 6F-p53-/-MEF suspension cells stained with mature lineage surface markers. 
60% (CD11b, Gr-1)+, 10% (CD11b, Gr-1)+/CD45+ indicating granulocyte/macrophage population; 1% Ter119+, 0.7% 
Ter119+/CD71+ indicating erythrocyte population; 2.6% CD41+/CD61+ indicating mature megakaryocyte population; 





 4.2.3. IN VITRO CFC ASSAY 
Day 30 post-infection suspension cells were collected and assayed for progenitor 
potential by colony assay. After 15 days in semi-solid culture conditions, red colonies 
(BFU-E), myeloid colonies (CFU-GM), and mixed colonies (CFU-GEMM) were 
observed (Figure 15).  
Representative colonies of each type were picked and stained for nuclear morphology, as 
well as, for the presence of hemoglobin in the case of erythroid colonies. As seen in 
Figure 15A and Figure 16A, red erythroid colonies are in fact benzidine-positive. These 
colonies contained a mix of both benzidine stained and non-benzidine stained cells. 
Benzidine negative cells, are not hemaglobinized, but have the cellular morphology of 
blast cells very similar to immature blood cells. White, myeloid colonies were found to 
contain neutrophils and macrophage. Neutrophils are characterized by their classical  
“horse-shoe” shaped, or donut shaped nucleus. A “kidney-bean” shaped nucleus, and 
accompanying clear spot, characterize monocytes, precursors to macrophages. Exemplars 




Figure 15. Colonies from 30 d.p.i. 6F-p53-/-MEF suspension cells in CFC assay. Bright-field images of colonies 15 







Figure 16. Nuclear morphology of 15-day CFC colonies from 30 d.p.i. 6F-p53-/-MEF suspension cells. Colonies 
were picked directly from semi-solid media culture, stained and visualized under bright-field; A) Erythroid colony: 
cells show positive staining for benzidine, and are counterstained with Wright-Giemsa (nucleus); B) Myeloid colony: 
stained with Wright-Giemsa showing classic donut shaped nucleus of a neutrophil; C) Myeloid colony: stained with 
Wright-Giemsa showing a “kidney-bean” shaped nucleus characteristic of a monocyte. Images taken using a Leica DM 







4.2.4. IN VIVO REPOPULATION ASSAY 
In vitro studies suggested 6F successfully reprogrammed p53-/-MEFs into hematopoietic 
progenitors with multilineage erythro-myeloid differentiation ability. However, in order 
to definitively name the cells we produced as authentic hematopoietic progenitors, or 
stem cells, we had to assess their repopulative ability under in vivo conditions. Thus we 
transplanted reprogrammed fibroblasts into sub-lethally irradiated NSG mice, and 
examined their ability to successfully home to bone marrow and contribute to adult 
hematopoiesis. In order to track reprogrammed cells after transplantation, we first 
transduced 6F-p53-/-MEFs with a retroviral drive GFP expression vector to label these 
cells for at least 16 weeks post infection. Transplanted mice were assessed for 
hematopoietic contribution of injected cells by sampling peripheral blood and examining 
for GFP+ cells at 4 weeks and 16 weeks post-transplant (w.p.t.) in order to permit time for 
homing, engraftment, and mature cell reconstitution.  
Four weeks post-transplant, a small by detectable 2% population of GFP+ cells were 
found in peripheral blood (Figure 17). Of this GFP+ population, 65% were found to be 
double positive for both Ter119 and CD71, an indication of erythroid maturation. A 
considerable population of CD41+ cells was also detected, denoting a group of primitive 
progenitors as the population was not also CD61+, and thus not megakaryocytic. Thus at 
4 weeks, there is evidence of reprogrammed fibroblasts contributing to peripheral blood, 
with a suggestion that they also successfully engraft into bone marrow. At 16w.p.t. 
however, we did not observe any detectable GFP+ population in peripheral blood or bone 




Figure 17. FACS analysis of peripheral blood of 6F-p53-/-MEF at 4 weeks post-transplant. Injected NOD/SCID 
mice 4 weeks post-transplant; A) Upper histogram: from bone marrow injected control mouse; Lower histogram: from 
GFP-labeled 30 d.p.i. suspension cell injected mouse; B) Dot plots of GFP+ population showing 95% CD41+; no 
mature megakaryocytes (CD41+/CD61+); 65% population of CD71/Ter119 co-positive mature erythrocytes; All 








Figure 18. FACS analysis of peripheral blood of NOD/SCID mice at 16 weeks post-transplant. Left histogram: 
bone marrow injected control mouse; Right histogram: GFP-labeled 30 d.p.i. 6F-p53-/-MEF suspension cell injected 






Our work with p53-/-MEFs collectively suggest that reprogramming into the 
hematopoietic lineage is still capable without the use of powerful oncogenes (MT) as was 
previously used in our experiments with the Runx1-GFP reporter line. Moreover it also 
confirmed previous results as successful reprogramming events as opposed to aberrant 
results generated from oncogene driven expansion of inherent hematopoietic cells 
lingering in culture.  
Both with and without the use of oncogene overexpression, resultant reprogrammed 
suspension cells were remarkably similar in several ways. Cell surface marker analysis 
identifies several marker combinations that identify these cells as mainly myeloid cells 
within the hematopoietic lineage. The results gathered from cell surface markers so 
convincingly show an entrance again into the hematopoietic lineage, more specifically, 
into the myeloid fraction of the blood lineage (Figure 14). We were unable to find 
populations staining positive for the mature lymphoid lineage, however, as we addressed 
before, this may be entirely due to the constraints of our culture system.  
Within the hematopoietic field itself, the ex vivo culturing of primary HSCs without loss 
of stem cell potential is notoriously difficult. However, prodigious studies done have 
revealed an extensive network of cytokines involved in proliferation and differentiation 
within this system. It is from these studies that we decided upon a classic cocktail of 
cytokines with which to culture and capture likely reprogrammed cells. Thus we changed 
our in vitro culture system in two ways to more closely reflect the in vivo niche in which 
HSCs and progenitors develop. By adding a feeder layer of stromal cells and utilizing 
cytokines previously shown to enhance the culture of hematopoietic stem and progenitor 
cells, we gave ourselves not only an additional assay with which to characterize our cell, 
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but a better chance at extending the life of any induced hematopoietic cells that were 
generated as well. While the CAFC assay is only one of many assays used to assess the 
identity of our cells, as assessment occurred at an earlier time point than assessment by 
cell surface markers, it was a useful tool to quickly identify if we were on the right track. 
As shown in Figure 12, our reprogrammed cells do form colonies that are strikingly 
similar, morphologically, to bone marrow derived hematopoietic progenitors.  
However, colony morphology is not enough to conclusively label our 6F-p53-/-MEFs as 
hematopoietic progenitors, nor does it tell us what kind of progenitors they are (e.g. 
myeloid or lymphoid), or of their potency (e.g. ST-HSC, or MEP). To that end, we 
employed further in vitro assays meant to measure the potential of the reprogrammed 
cells to differentiate and mature into cells of the hematopoietic lineage. Through the use 
of methylcellulose colony assays, we showed that 6F-p53-/-MEFs were able to 
differentiate into morphologically similar macrophage, granulocyte, and erythrocyte cells 
(Figure 16) when compared to biological samples. Thus not only did our culture already 
display a characteristic of hematopoietic cells in culture, specifically suspension viable 
cells, but they also contained progenitors within that population. Once these progenitors 
were exposed to cytokines appropriate for the differentiation of mature hematopoietic 
lineage cells, we could assess their progenitor potential by examining resulting colonies. 
What we found was that suspension cells were comprised of progenitors displaying both 
uni- and bi-potentiality. This was exhibited by the outgrowth of colonies comprised of 
one or two mature cell types. These colonies of mature cells were classified as CFU-M, 
CFU-G, CFU-GM, as well as BFU-E (Figure 15). Nuclear staining of these colonies also 
supported their classification. As shown in Figure 16, our colonies did contain mature 
cells showing characteristic nuclear morphology of monocytes, macrophages, and 
granulocytes. Moreover, colonies that appeared red under bright-field microscopy did 
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react to benzidine as expected and thus contained hemoglobin. When compared against 
published examples of BM derived colonies in the same assay, our colonies are 
indistinguishable. We can conclude that we are generating at least bi-potential 
progenitors of the myeloid lineage. We did see, albeit rare, colonies in which both 
neutrophils and erythrocytes were present in the same colony, thus there were CMPs 
present within the suspension fraction of our cultures. The lack of lymphoid colonies in 
this semi-solid culture seems to indicate that the elusive HSC, or MPP, was not part of 
our reprogrammed cells. However as with the liquid culture, there is an understood 
limitation to the semi-solid culture that favors the outgrowth of myeloid colonies as 
opposed to lymphoid. Ultimately the most optimal test of our reprogrammed cells’ 
potential lies in in vivo assays.  
Therefore, we tested 6F-p53-/-MEF under in vivo conditions by transplantation into the 
NSG mouse line. By previous ubiquitous tagging our cells with GFP expression, we were 
able to track our cells in the mouse at 4 and 8w.p.t. While at 4w.p.t. we did see a modest 
population of cells in peripheral blood expressing GFP (Figure 17). Assessing these cells 
for identity through cells surface marker resulted in a contribution to the myeloid lineage 
and not the lymphoid lineage. This would imply limited progenitor capability in the 
injected cell population, but not HSC potential. Additionally, as we were unable to see 
any indication of reprogrammed cell contribution to peripheral blood at 8 weeks, we can 
conclude that we definitely did not inject any viable cells with HSC capability (Figure 
18).  
Therefore this experiment revealed that, much like iPS experiments, the increased cell 
cycling due to p53 knockdown was able to replace the function of oncogene expression 
and induce a change in cell identity. The addition of the CAFC assay gave us another 
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level of morphological characteristics indicative of not only hematopoietic cells but of 
progenitors within the lineage. Collectively all in vitro assays specify successful 
reprogramming of p53-/-MEFs into myeloid hematopoietic cells, with limited progenitor 
ability. There are hints of having generated as primitive a progenitor as the CMP, 
however the majority of these progenitors are transient in our culture and, most likely, 
quickly continue down the differentiation pathway into the uni- or bi-potential 
progenitors. This conclusion is upheld by the in vivo assay results. Once again we are 
seeing very modest contribution to peripheral blood, thus not an indication of more 
upstream progenitors such as the HSC, or MPP. The lack of lymphoid lineage even 
within in vivo conditions seems to uphold this conclusion. Collectively, our results 
suggest that overexpression of select HSC nuclear regulators in fibroblasts under 
optimized culture conditions has successfully reprogrammed p53-/-MEFs into multipotent 
hematopoietic progenitors with erythro-myeloid differentiation potential.  
Thus since we have been successful in reprogramming MEFs into the hematopoietic 
lineage with a rather big pool of hematopoietic related TFs, it became obvious to us to 
explore the possibility that our pool of 6 factors are not all need to incite such a drastic 
change in cellular identity. Therefore we endeavored to narrow down the minimal factors 









SCREENING FOR MINIMAL TRANSCRIPTION 









We hypothesized that the 6F previously tested was not the optimal combination of factors 
to use in order to induce the hematopoietic pathway. This was suggested by both previous 
work in inducing the pluripotent cell state, utilizing only 3 factors, as well as previous 
work indicating only a subset of our exogenous genes were being expressed in our 6F 
induced hematopoietic cells. We also remained unconvinced that Runx1 was not 
necessary for inducing the hematopoietic program since it is so crucial during 
hematopoietic development. We reexamined the possible role Runx1 could play by 
including it again in this list of combinations to test. Thus we set out to test for the 
minimal combination of hematopoietic factors that can still induce fibroblast into the 
hematopoietic pathway. Taking advantage of the proliferative ability of p53-/-MEF, we 
tested across 12 different factor combinations.  
Our main goals changed in this set of experiments. As we were looking for the minimal 
combination of factors able to generate hematopoietic progenitors specifically, we 
modified our analysis to reflect this. Therefore, we assessed the progenitor potential in 




5.2.1. IN VITRO MORPHOLOGICAL CHANGES AND CAFC 
Since this is a rather arduous and long process, we used a chronological approach to 
assess the success of the different combinations. The earliest changes seen were 
morphological, thus the first assay to show distinct results was the cobblestone area 
forming cells assay. 8 different factor combinations yielded cobblestone like colonies as 
seen in Figure 19. Surprisingly, the combination of only Scl and Lmo2 (SL) together was 
enough to induce cobblestone like morphology, but at a very low efficiency rate. This SL 
combination was enough to induce morphological changes but was unable to produce 
viable suspension cells. The remaining 7 combinations were able to induce the classical 
“cobblestone” cell morphology as well as generate the accompanying suspension viable 
cells. Out of those 7, one combination stood out in particular, the SLHR (Scl, Lmo2, 
Hoxb4, and Runx1) 4-factor combination produced the most robust number of cells 
exhibiting hematopoietic-like adhesion independence. This combination also produced 
far more viable suspension cells than our previously studied 7F(-R) combination, without 
Runx-1. Cobblestone colonies from representative combinations can be seen in Figure 
20. The lack of suspension cells under SL factor reprogramming can be seen in that same 
figure. Both SLH and SLHB combinations were also capable of producing cobblestone 




Figure 19. Cobblestone colony counts at 20dpi of p53-/-MEF on OP9 stromal cell feeder layer reprogrammed with 






Figure 20. Cobblestone colonies of p53-/-MEF at 28d.p.i. A) SL-p53-/- MEF (40x); B) SLHR-p53-/- MEF showing 
both less refractive adherent cobblestone-like cells and associated highly refractile semi-adherent suspension cells 
(40x); C) 7F(-R)-p53-/- MEF also showing both a less refractive cobblestone colony with bright suspension viable cells 
(40x); D) 7F(-S) does not generate cobblestone colonies at all, as revealed by a field of normal fibroblast morphology 






5.2.2. SURFACE MARKER CHARACTERIZATION BY FACS ANALYSIS 
Morphology helped to narrow down the possible combinations to 7 successful formulas. 
However, to confirm hematopoietic progenitors identity, we looked at cell surface 
markers. Thus we employed what we knew about the hematopoietic system to select for 
an appropriate marker that would be able to identify a wide range of cells with progenitor 
ability. Since the CAFC assay is able to identify progenitor cells, both primitive and 
committed, we looked to identify which combination of factors was better at producing 
progenitors by examining for expression of c-Kit. We then stained viable suspension cells 
for the cell surface marker c-Kit. This surface marker is expressed on a wide range of 
cells with progenitor identity, from the stem cell to the committed progenitor. Of the 7 
combinations that produced viable suspension cells, only 4 conditions showed a 
population of c-Kit positive cells, SLH, SLHB, SLHR and 7F(-R). As can be seen in 
Figure 21, of those 4 conditions, the SLHR combination yielded a population of 5% c-
Kit+ cells, with SLH generating the highest population (11%) of this trial.  
To further ensure that we had in fact entered into the hematopoietic system, those same 
suspension cells were further assayed for other more mature hematopoietic surface 
markers. FACs assayed cells for mature lineage marker combinations routinely used to 
identify mature blood cells of the myeloid and lymphoid lineages are shown in Figure 22 
and Figure 23. Suspension SLHR infected cells showed evidence of mature myeloid 
populations. There was a 19% population of megakaryocytes, indicated by a co-
expression of CD41 and CD61. A 6% population co-positive for Gr-1 and CD45 marked 
mature granulocytes, while a 4% co-positive population of CD11b and CD45 cells 
indicated mature macrophages (Figure 22). When assaying for mature erythroid cells, 
there was a low to no population staining positive for both Ter119 and CD71. There was 
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a complete lack of lymphoid cells detected in suspension as seen by no percentage of 
suspension cell staining positive for B220 or CD19, indicative of B-cells, or CD3, 4, or 8, 
indicating T cells and NK cells (Figure 23).  
Suspension cells from the SLH combination was also assayed in a similar manner (not 
shown), and also performed similarly, staining positive for CD11b, and Gr-1, within the 
myeloid lineage. The lymphoid markers B220, CD19, CD3, CD4, and CD8, also were 
not found within the viable suspension cells. Interestingly, live cell gating revealed a 
slight reduction in the percentage of viable suspension cells in the SLH condition versus 






Figure 21. FACs analysis of 30d.p.i. suspension cells of reprogrammed p53-/- MEFs. c-Kit staining is shown in three 
panels, with positive stained population percentages labeled. A) Unstained control showing less than 1% positive 
staining; B) SLHBR-p53-/-MEF yields a 2% positive population; C) SLH-p53-/-MEF generated the highest percentage 







Figure 22. FACs analysis of myeloid cell surface markers of SLHR-p53-/-MEF suspension cells at 31d.p.i. A) 19% 
population of CD41+/CD61+ cells denotes mature megakaryocytes, 12% CD41+ and 18% CD61+ single positive 
populations; B) A 6% population of Gr-1+/CD45+ labels mature granulocytes, 30% Gr-1+ and a 1% CD45+ single 
positive populations; C) 4% CD11b+/CD45+ double positive marking mature macrophages, 6% CD11b+ and 4% CD45+ 

























Figure 23. FACs analysis of lymphoid cell surface markers of SLHR-p53-/-MEF suspension cells at 31d.p.i. A) B 
cell mature lineage markers pooled: 0% (B220, CD19)+ or (B220, CD19)+/CD45+ double positive, 12% CD45+ single 
positive population; B) T cell mature lineage markers pooled: 0% (CD3, 4, 8)+ or (CD3, 4, 8)+/CD45+ double positive, 





















5.2.3. IN VITRO CFC ASSAY 
Colony forming cell assay allows us to identify the population of progenitors by 
assessing the differentiated colonies that result. Suspension cells of the remaining 4 
combinations were placed into the colony forming cell assay. This assay tests for identity 
of progenitors by testing their differentiation potential. The suspension cells were placed 
into a semi solid media to ensure colonies arose from only one cell, and were cultured 
under cytokines necessary for the differentiation and maturation of all myeloid lineages. 
In this assay we again identified the SLHR combination as possessing the most number 
of unique differentiated colonies, representatives of which can be seen in Figure 25, 
including rare occurrences of colonies comprised of granulocytes and erythrocytes, 
implying the existence of a CMP in suspension. The SLHR combination contained 
megakaryocyte colonies, not found in the other factor combinations. Other combinations 
also yielded colonies, however no other combination showed colonies containing more 
than one cell type, indicative of a suspension populated by committed progenitors. Figure 
24 highlights the difference in colony formation across these factor combinations. The 
SLHR combination was able to produce the most colonies in total, as well as able to 
generate the most BFU-E colonies as found by their characteristic red color. While the 
SLH combination was able to produce competitive numbers of colonies, these colonies 
were limited in their diversity when assayed for nuclear morphology (not shown).  
To conclusively identify types of colonies produced by the CFC assay, Wright-Giemsa 
staining was again employed. Single colonies were picked from the semi-solid media, 
and stained for nuclear morphology, as well as for the presence of hemoglobin. By 
picking single colonies for staining, we can also assay for the number of cell types within 
one colony, thus identifying how primitive the colony’s cell of origin was. The most 
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common colony type seen across different combinations were of granulocyte and 
macrophage identity. When these types of colonies were stained, normal nuclear 
morphology was seen. However, as seen in Figure 26, the SLHR combination yielded 
colonies with more than one cell type, as shown by the presence of red cells, benzidine 
positive, in the same colony as a megakaryocyte. These colonies indicate a MEP. There 
were also colonies comprised of red cells and granulocytes. Since the divergence between 
red cells and granulocytes occur more upstream of the MEP, these colonies indicate the 
originating cells to be a CMP. Thus the SLHR combination gave rise to more primitive 
progenitor cells than the other combinations.  
FACs staining of SLHR suspension cells showed a rather robust population of mature 
granulocytes. Mature granulocytes have distinct nuclear morphology, which can be 
elucidated by utilizing Wright-Giemsa staining. To confirm that we had attained normal 
mature granulocytes in suspension as indicated by cell surface marker staining, we then 
stained our suspension cells to assay for normal nuclear granulocyte morphology. It is 
clear from Figure 27, our cells do show nuclear morphology indicative of granulocytes, 
evidenced by characteristic horseshoe shaped nuclei. One can also see the more primitive 
monocytes, characterized by kidney bean shaped nuclei. Suspension cells showed normal 




Figure 24. Summary of CFC assay colony counts of p53-/-MEF showing CFU-GM and BFU-E (Red) colonies per 
10,000 cells plated. Of the 4 TF combinations assayed, the SLHR combination gave the most colonies per 10,000 cells, 
of both granulocyte/macrophage and erythroid type colonies. Counts were done at 15 days after plating onto semi-solid 































Figure 25. Bright-field images of SLHR-p53-/-MEF suspension cells colonies in CFC assay at 15 days. A) CFU-M 









Figure 26. Bright-field images of cytospin preparation of SLHR-p53-/-MEF suspension cell CFC assay colonies. 
A) Wright-Giemsa staining of CFU-M showing a macrophage, and monocyte; B) Wright-Giemsa staining of CFU-G 
showing an eosinophil, and two neutrophils; C) Wright-Giemsa staining of CFU-MK showing a megakaryocyte; D) 
Benzidine counterstained with Wright-Giemsa of BFU-E showing multiple hemaglobinized cells in the field; E) 
Benzidine counterstained with Wright-Giemsa of CFU-GEMM, note the presence of a monocyte next to two 










Figure 27. Cytospin of SLHR-p53-/-MEF suspension cells at 31d.p.i. stained with Wright-Giemsa for nuclear 
morphology. The field shows characteristic U-shaped and donut shaped neutrophil nuclear morphology, as well as a 





5.2.4. IN VIVO REPOPULATION ASSAY 
To further assess SLHR-p53-/-MEF cells, we then moved into in vivo assays, namely the 
transplant assay in NSG mice. Since c-Kit+ populations include the stem cell, we wanted 
to test for the presence of the stem cell by placing them in the optimal environment, the 
mouse bone marrow, and assaying for the ability to proliferate and differentiate under 
biological conditions.  
We harvested the c-Kit+ population from 30d.p.i. cultures, and injected them into 8 week 
old NSG mice. Mice were then assayed at 4w.p.t. for the presence of injected cells. This 
was done by CD45 isoform comparisons. The NSG mouse expresses the CD45.1 
isoform, while the p53-/- mouse, and thus our experimental cells, express the CD45.2 
isoform. However, at 4w.p.t., we were unable to find any contribution to peripheral blood 
by SLHR-p53-/-MEFs when analyzed by transduced GFP expression or CD45.2 antibody 






In conclusion we determined that the minimal combination to induce p53-/-MEFs into the 
hematopoietic system was Scl, Lmo2, Hoxb4, and Runx1 (SLHR). This combination of 
factors was able to produce cells that showed colony morphology indicative of 
hematopoietic progenitors. It also produced viable suspension cells that were able to 
differentiate in suspension into mature myeloid lineages. These suspension cells 
expressed the appropriate cell surface markers indicative of mature hematopoietic 
granulocytes (Gr-1+), macrophages (CD11b+), megakaryocytes (CD41+/CD61+), as well 
as progenitor marker c-Kit (Figure 22 and Figure 21). Normal nuclear morphology was 
seen when suspension cells were stained by Wright-Giemsa (Figure 27). When progenitor 
potential was assayed, this combination produced the most robust number of colony 
formation, as well as the most diverse types of colonies produced (Figure 24 and Figure 
25). The colony forming cell assay also identified this combination as producing more 
primitive progenitors, as evinced by the formation of colonies comprised of multiple 
different cell types. In total the in vitro assays point to the minimum factors as SLHR. 
This combination of factors does induce cells into the hematopoietic lineage, with a 
robust population of progenitor cells.  
The SLH combination of factors also produced comparable cobblestone colonies, and 
performed similarly in the CFC assay, when evaluated against SLHR. However, we did 
notice a decline in the percentage of live cells found in the suspension, as determined by 
side and forward scatter during FACS analysis of surface markers. This observation 
correlated with the fact that MEF cultures infected with SLH were not able to produce 
viable suspension cells for the same span of time as SLHR infected cultures. As HSCs are 
also identified by their persistence of hematopoiesis in culture, as determined through the 
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long-term culture-initiating cell assay (Sutherland et al. 1989; Lemieux et al. 1995); we 
looked upon the more rapid exhaustion of SLH culture as indication of more committed 
progenitors.    
Cobblestone colony formation across all factor combinations examined summarized in 
Figure 19 produces an interesting trend. Any combination in which Scl or Lmo2, or both, 
were missing did not produce any cobblestone colonies. This confirmed what we had 
previously seen, in which Scl and Lmo2 exogenous genes were still expressed in all 
colonies picked from the colony forming cell assay in the 7F-p53-/-MEF (not shown). In 
fact, the SL combination alone was able to generate cobblestone-like colonies. However, 
a successful cobblestone colony is also characterized by the production of viable 
suspension cells. As the SL combination was unable to yield suspension cells, we did not 
consider this combination a success.  
Through both co-culture colony morphology and cell surface markers (c-Kit+), we 
identified 4 factor combinations able to produce progenitor populations within our 
culture. We also positively confirmed that we had successfully attained the hematopoietic 
lineage. However, since those methods identified a wide array of progenitor cells, we 
wanted to know the composition of this population. This was important since we were 
looking for a combination of factors that would yield the most diverse range of 
progenitors. The expression of c-Kit on the cells surface indicated a progenitor identity, 
but it did not tell us if the cells were stem cells, MPPs, CMPs, GMPs, MEPs, or further 
committed progenitors. We relied on the CFC assay to aid our identification of such 
progenitors. Results from this assay also indicated SLHR as having a greater ability to 
produce progenitors than seen in the other combinations (Figure 24). Moreover, SLHR-
p53-/-MEF suspension cells were able to produce a wide range of colony types (Figure 
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25). Progenitor potential identified a range of progenitors in suspension, from primitive 
CMP to committed erythroid, granulocyte, monocyte, macrophage and megakaryocyte 
progenitors. These colony morphologies were again confirmed by nuclear staining. 
Collectively the in vitro characterization of SLHR-p53-/-MEF indicates these cells have 
successfully reprogrammed into the hematopoietic lineage. Co-culture morphology seen 
in the CAFC assay, cell surface marker, and CFC assay distinguished this combination as 
the most prominent producer of both mature lineage populations as well as diverse 
progenitor population. However, the ultimate test of these reprogrammed cells’ identity 
and ability lie under biological conditions such as in vivo mouse transplant assays. 
The in vivo transplant assay did not yield evidence of any engraftment by SLHR-p53-/-
MEFs. Peripheral blood examined, for the presence of GFP-tagged donor cells, at 4w.p.t. 
failed to identify a population. While this combination performed well under in vitro 
assays, under in vivo conditions, they failed. By testing peripheral blood at 4 weeks, we 
were surveying transplanted cells for stem cell proliferative ability. Stem cells, be they 
short-term or long-term, have the ability to home to bone marrow and engraft in the 
appropriate niche, before proliferating and differentiating into the mature cells that 
comprise the peripheral blood. Therefore contribution to peripheral blood at 4 w.p.t. is 
the first indication of HSC ability. The fact that we did not see contribution at 4 weeks 
does designate a lack of HSC faculty in our reprogrammed cells, but does not exclude the 
possibility of other more restricted progenitor characteristics. The more restricted 
progenitors, such as the CMP or GMP, do not survive that long in transplant assays as 
they are unable to self-renew. Thus transplanted restricted progenitors are not deemed to 
contribute to peripheral blood 4 weeks or more after transplant. This being said, as we did 
not assay our transplanted mice earlier than 4w.p.t., we did not examine the function of 
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any restricted progenitors generated by SLHR-p53-/-MEFs. Moreover, while the SLHR-
p53-/-MEF reprogrammed cells did not show an ability to differentiate into the lymphoid 
system in vitro, we hypothesized this may be due to our culture system. The culture 
system and differentiation assay we employed does have a bias towards the myeloid 
program. Thus we suspected our cells would, given proper conditions, be able to 
differentiate into both the myeloid and lymphoid programs. This unfortunately, was not 
the case in vivo.  
In short, in vitro assays identified SLHR as the minimum combination of transcription 
factors able to reprogram p53-/-MEFs into the hematopoietic lineage. This combination 
was able to generate bi-potential progenitors within the myeloid lineage, capable of 
differentiating into normal mature myeloid cells. The in vivo transplant assay did not 
identify HSC ability within the progenitors produced by SLHR-p53-/-MEFs. However, 
the in vivo interrogation of restricted progenitors produced by this combination remains 








CHARACTERIZATION OF INDUCED 










Concurrent with inducing hematopoietic identity in p53-/-MEF, we also tried 
reprogramming into the hematopoietic lineage on a wild-type (WT) background. Since, 
we had seen that the combination of 4 factors (SLHR) was most efficient at inducing not 
just hematopoietic identity, but also produced a population of cells expressing the 
progenitor surface marker c-Kit, we decided to utilize this combination in WT MEF. We 
used MEFs expressing red fluorescent protein, Dsred, in a ubiquitous manner (Muzumdar 
et al. 2007) as our target cells, to aid in the identification of our cells in further down 
stream assays, specifically in vivo assays.  
The WT target cells (MEFs) were derived from a genetically modified mouse strain in 
which the Dsred protein has been knocked-in to the ROSA26 locus (Muzumdar et al. 
2007). This mouse strain expresses red fluorescence protein (Dsred) in all tissues and 
cells types. As this knock-in mouse strain remained phenotypically normal in all other 
respects, we considered it a valid WT genetic background with which to test our minimal 
combination of factors. This global Dsred expression persists throughout the 
hematopoietic system, from BM to circulation. Therefore, we made use of this reliable 
tracking system to enable us to assess the performance of SLHR transfected Dsred-MEFs 
(SLHR-Dsred-MEF) in vivo.  
As the target cells were derived from primary fetuses, we were concerned about the 
possibility of contaminating hematopoietic cells within the fibroblast culture. Therefore, 
as in the p53-/-MEF culture, we again sorted out any cells expressing any hematopoietic 
surface marker, from mature to HSC. This depleated culture of fibroblasts was then used 
for reprogramming.  
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Here again we interrogated our reprogrammed cells for hematopoietic identity in a step-
wise manner (refer to Figure 10). First, morphological changes were observed in the 
CAFC assay. When suspension cells were observed, these cells were probed for 
hematopoietic identity by cell surface marker staining. Suspension cells were also placed 
into the CFC assay to measure progenitor potential. Resultant colonies were stained for 
nuclear morphology, as well as benzidine to confirm colony identity by morphological 
characteristics. Ultimately, suspension cells were assayed for reconstitution, and 
progenitor potential under biological conditions through the in vivo transplant and CFU-S 
assays. Multiple hematopoietic tissues were assessed for contribution by single cell 





6.2.1. IN VITRO MORPHOLOGICAL CHANGES 
Employing the same in vitro assays, we found that even on the WT background, the 
SLHR combination was able to produce cobble stone colonies. As shown in Figure 28, 
these 23d.p.i.  colonies do exhibit the characteristic cluster of less refractive cells, and are 
accompanied by copious viable suspension cells. Moreover, these colonies are comprised 
of Dsred cells, thus originating from our induced MEF as opposed to OP9 cells. The 
kinetics of these cobblestone colonies formed slightly slower than on the p53-/- 
background. This is to be expected, as one diagnostic feature of the p53 knockout line is a 
faster cell cycling. Viable suspension cells were also generated in culture at 28d.p.i., 




Figure 28. 23d.p.i. SLHR-Dsred-MEF cobblestone colonies under bright-field and Dsred fluorescence. Note the 
large numbers of highly refractile semi-adherent cells surrounding colonies of packed, dark, less refractile cells on the 
adherent layer. Images taken on Zeiss Axio Observer.D1. 
 
BrightQfield Dsred& Overlay 
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6.2.2. SURFACE MARKER BY FACS ANALYSIS  
Suspension cells were then analyzed with cell surface markers by flow cytometry for 
expression of c-Kit. Surprisingly, this combination on the WT background yielded a 
greater percentage of c-Kit+ cells versus the p53-/-MEF. As seen in Figure 29, suspension 
cells at 28d.p.i. are viable and Dsred positive, moreover, there is also a 8% population of 
c-Kit+ cells. Again, this c-Kit+ cell population includes progenitors of multi-lineage, 
restricted and committed potential (Lyman and Jacobsen 1998; Sharma et al. 2006). 
Interestingly, the c-Kit+ population was sustained in suspension up to 38d.p.i. before 
noticing a drop in percentage. This can be attributed to the aging of the culture, as this 
trend is also noticeable in the p53-/- background, and we have by no means attained a 
culture system that is able to preserve the pluripotent hematopoietic stem cell in 
perpetuity. 
Mature lineage marker staining of these suspension cells yielded small populations of 
mature myeloid cells, and no indication of mature lymphoid cells (Figure 29B). For 
example, 28d.p.i. suspension cells generated 3% CD11b+/CD45+, 4% Gr-1+/CD45+ 
(Figure 29B). Interestingly suspension cells did stain for abnormal CD11b+/CD45- (10%) 
and Gr-1+/CD45- (68%) not normally seen under biological conditions. Strikingly cells 
stained for B and T-cell mature lineage markers failed to produce a population positive 




Figure 29. FACs analysis of 28d.p.i. SLHR-Dsred-MEF suspension cells. A) Histogram showing suspension cells 
are Dsred+; B) Mature lineage staining of suspension cells showing 3% CD11b+/CD45+, 10% CD11b+/CD45-, 4% 
Gr-1+/CD45+, 68% Gr-1+/CD45-, 0% (B220, CD19)+/CD45+, 5% (B220, CD19)-/CD45+, 0% (CD3,4,8)+/CD45+, 
4.8% (CD3,4,8)-/CD45+; C) Unstained sample of suspension cells; D) Staining for c-Kit progenitor marker showing an 
8% c-Kit+ population; All analysis done on FACSAria (BD Biosciences). 
 
! ! !!118!
6.2.3. IN VITRO CFC ASSAY 
We tested progenitor potential in SLHR-Dsred-MEF by introduction into the 
methylcellulose colony assay, as described before. At 16 days in semi-solid media we 
saw an outgrowth of various myeloid colony types, namely CFU-G, CFU-M, and CFU-
GM (Figure 30). This assay did not exhibit any erythroid colonies, either CFU-E or BFU-
E, as assessed by a lack of hemaglobinized colonies in culture. Individual myeloid 
colonies were picked and stained for nuclear morphology by Wright-Giemsa staining, 
and revealed mainly neutrophils, macrophages, and some eosinophils (Figure 31). 
Interestingly, when 34d.p.i. SL-Dsred-MEF suspension cells were placed into the 
methylcellulose colony assay, we found convincing BFU-E colonies in culture (Figure 
32A). The presence of hemoglobin was confirmed with benzidine. As you can see in 
Figure 32B, while the combination of SL alone was able to produce red, erythroid 
colonies, the over all colony count was remarkably decreased. In terms of total progenitor 
potential in suspension, the SLHR combination still yielded more colonies when 





Figure 30. 16 day CFU counts of 28d.p.i. SLHR-Dsred-MEF suspension cells. CFU-G (granulocytes), CFU-M 





























Figure 31. Images of 16-day CFU colonies of 28d.p.i. SLHR-Dsred-MEF suspension cells; A) Bright-field images 
of representative CFU-G, CFU-M, and CFU-GM colonies seen in methylcellulose culture, 100x; B) Wright-Giemsa 
staining of cytospin slides prepared from the colonies seen in (A), showing a neutrophil on the left, a macrophage in the 
middle, and both a macrophage and granulocyte on the right, using a Leica DM LB2 (Leica Microsystems). 
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Figure 32. 16 day CFU assay of SL-Dsred-MEF suspension cells. A) Bright-field image of BFU-E (erythroid) 
colony from 34d.p.i. SL-Dsred-MEF suspension cells, 200x; B) Benzidine counterstained with Wright-Giemsa stain of 
a cytospin slide prepared from the BFU-E shown above in which numerous benzidine positive cells can be seen in the 
image on the left (200x), image on the right shows two individual benzidine positive cells at 400x magnification, on a 
Leica DM LB2 (Leica Microsystems); C) Chart of total CFU colonies seen from 34d.p.i. SL-Dsred-MEF and SLHR-
































6.2.4. IN VIVO REPOPULATION ASSAY 
Suspension cell from SLHR-Dsred-MEF cultures were transplanted into sub-lethally 
irradiated (5.5Gy) C57BL/6 mice and assayed at 2, 3, and 4 weeks post-transplant for 
contribution to PB. As seen in Figure 33, the percentage of Dsred contribution to PB is 
evident at 2 weeks, but steadily declined to the point where it is undetectable at 4 weeks 
post-transplant. 31d.p.i. SLHR-Dsred-MEF suspension cell contribution to individual 
mice can be seen in Figure 34A, ranging from 2-6.8% of total mononuclear PB cells. 
Furthermore, when Dsred cells were interrogated for mature lineage identity by cell 
surface marker staining, 2 mice showed lymphoid populations; namely B-cells 
(B220/CD19)+, and T-cells (CD3,4,8)+ (Figure 34B). Staining was done on a control 
mouse, injected with vehicle only, to provide a comparison of normal proportions of 
mature lineages in PB (Figure 34C). 
The same analysis was conducted on PB at 3 weeks-p.t. Figure 35A shows total Dsred 
cells found in PB, ranging from 0.5-1.2% of total mononuclear cells. When Dsred cells 
were stained for mature lineage markers, only macrophages (CD11b+), granulocytes (Gr-
1+), and erythrocytes (Ter119+) were found in mice at this time, with a notable absence of 
B-cell (B220, CD19) or T-cell (CD3,4,8) markers staining positive (Figure 35B). 
Moreover, by 4 w.p.t., peripheral blood failed to show any Dsred population. Mouse bone 




Figure 33. Summary of FACs analysis of total Dsred percentage detected in peripheral blood of mice injected with 



















Figure 34. 2-week post-transplant peripheral blood analysis of 31d.p.i. SLHR-Dsred-MEF suspension cells by 
FACs single cell staining. A) Total Dsred percentage of 4 mice injected with 5x106 suspension cells, and 1 control 
mouse injected with vehicle only, showing Dsred contribution ranging from 2-~7%; B) Mature lineage analysis of 
Dsred+ fraction of experimental mice, in which B-cell (B220, CD19) contribution can be seen in all 4 mice, while only 

































































Figure 35. 3-week post-transplant peripheral blood analysis of 31d.p.i. SLHR-Dsred-MEF suspension cells by 
FACs single cell staining. A) Total Dsred percentage of 4 mice injected with 5x106 suspension cells, and 1 control 
mouse injected with vehicle only, ranging from 0.5-1.2% Dsred+; B) Mature lineage analysis of Dsred+ fraction of 
experimental mice, note a lack of contribution to B- or T-cell fractions ([B220,CD19] or [CD3,4,8] respectively) of PB; 






























































6.2.5. SPLEEN COLONY FORMING ASSAY 
SLHR-Dsred-MEF suspension cells were also assayed for spleen colonization in the 
CFU-S assay. As such, lethally irradiated (7Gy) C57BL/6 mice were IV injected with 
suspension cells and sacrificed at 14 days post-transplant (d.p.t.) to harvest spleen, PB, 
and BM, and analyzed for Dsred contribution across all mature hematopoietic lineages.  
When 27d.p.i. SLHR-Dsred-MEF suspension cells were assayed for spleen colony 
formation, numerous Dsred+ colonies were found in spleens (Figure 36A). PB was found 
to contain Dsred contribution ranging from 0.3-4.3% (Figure 37A). Donor derived Dsred+ 
cells contributed to all mature lineages mirroring what had been seen in the transplants 
assayed at weekly intervals (Figure 37B). However, not all mice transplanted with 
27d.p.i. SLHR-Dsred-MEF suspension cells contributed evenly with 2/6 mice showing 
only myeloid lineage contribution, B-cell contribution in 4/6 mice, and T-cell 
contribution in 2/6 mice. The modest Dsred contribution seen in peripheral blood was 
amplified when BM was assayed for contribution (4.4-27.1%) (Figure 37C). Striking 
similarities were seen in staining pattern of donor Dsred+ cells when compared to host 
cells stained with the same markers (Figure 38). 
We also placed 34d.p.i. SLHR-Dsred-MEF suspension cells through the same rigorous 
examination. These cells were also found capable of colonizing the spleen, producing 
copious amounts of Dsred+ colonies (Figure 36B). PB was assessed for Dsred 
contribution (1.7-2.3%; Figure 39A), and here we found higher percentages then 
previously seen from 27d.p.i. suspension cells. Dsred+ cells in PB was also found to stain 
for all mature lineage markers (Figure 39B), with an increased number of mice, 4 of 4 
mice injected, showing contribution to lymphoid lineages. However, when BM was 
interrogated for contribution, we failed to see a significant percentage of Dsred+ cells 
higher than 1%; or were double positive Dsred+/c-Kit+ populations convincing (Figure 
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39C). There was an apparent reduction of the gross number of spleen colonies from these 
“later-day” suspension cells when the whole spleen was viewed. Single cell analysis of 
these spleens revealed Dsred+ populations ranging from 9.2-19% of total spleen cells 
(Figure 40A). Donor derived Dsred+ spleen cells identified as CD11b+/CD45+, Gr-
1+/CD45+, Ter119+, CD41+/CD61+, (B220, CD19)+/CD45+, and (CD3,4,8)+/CD45+, 
representative of mature myeloid and lymphoid lineages (Figure 40B). Again, staining 
patterns between donor Dsred+ cells and host Dsred- cells could be seen in PB and spleen 
samples (Figure 41). 
As we still had viable suspension cells being produced in culture at 41d.p.i., we likewise, 
introduced these into the CFU-S assay. Again, spleens were colonized by Dsred+ colonies 
(Figure 36C). PB samples from this trial yielded comparative Dsred contribution (0.8-
2.8%; Figure 42A) when 27d.p.i and 34d.p.i. suspension cells were considered. Mature 
lineage marker staining of the Dsred+ population revealed Dsred+ cells were also 
CD11b+/CD45+, Gr-1+/CD45+, Ter119+, CD41+/CD61+, (B220, CD19)+/CD45+, and 
(CD3,4,8)+/CD45+, indicative of myeloid and lymphoid mature cells (Figure 42B). When 
BM was interrogated for Dsred contribution there was again a failure of any animal to 
show at least a 1% population within this tissue (Figure 42C). Spleens were also analyzed 
for Dsred+ percentages (2.3-11%; Figure 43A), as well as all mature lineage markers 
(Figure 43B). Here again Dsred+ cells were found in CD11b+/CD45+, Gr-1+/CD45+, 
Ter119+, CD41+/CD61+, (B220, CD19)+/CD45+, and (CD3,4,8)+/CD45+ fractions, 
indicating donor cell contribution to all mature lineages. Staining patterns of PB and 
spleen mature cells from donor SLHR-Dsred-MEF suspension cells and host C57BL/6 
hematopoietic cells were still comparable even at 41d.p.i. (Figure 44).  
As we had noticed a modest c-Kit+ population during surface marker analysis of in vitro 
SLHR-Dsred-MEF suspension cells, we enriched for c-Kit+/Dsred+ cells and introduced 
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them to the same in vivo scrutiny (Figure 45). Five million 27d.p.i c-Kit+ enriched cells 
injected into lethally irradiated mice yielded spleens showing copious numbers of Dsred+ 
colonies (Figure 47A). When PB was examined Dsred contribution varied from 7.9-14%. 
In BM Dsred+ percentage ranged from 13.3-19.7% (Figure 45B upper graph). Moreover, 
mature lineage staining of PB yielded one mouse showing Dsred donation to mature 
myeloid cell types (CD11b+/CD45+, Gr-1+/CD45+, Ter119+, and CD41+/CD61+), and 
mature lymphoid cell types ([B220, CD19]+/CD45+ and [CD3,4,8]+/CD45+), while the 
other mouse failed to contribute to the T-cell fraction of mature hematopoietic cells as 
that sample lacked a (CD3,4,8)+/CD45+ population within the Dsred+ cells (Figure 45B 
lower graph).  
37d.p.i. SLHR-Dsred-MEF suspension cells were also enriched for c-Kit+ cells by FACS 
sorting. Two mice IV injected with 1x106 c-Kit+/Dsred+ cells were assayed at 14 days 
post-transplant. Spleens were found containing Dsred+ colonies (Figure 47B) comparable 
to those formed by 5x106 total 34d.pi. SLHR-Dsred-MEF suspension cells examined at 
the same time (Figure 36B). BM, when observed for Dsred contribution did not yield 
significant populations (<1%) in any of the 2 mice injected. PB and spleen bore more 
significant percentages of Dsred+ cells ranging between 0.4-3.9% and 1.2-8.9% 
respectively (Figure 46A). Mature lineage marker staining of PB and spleen exhibited 
Dsred contribution into every mature hematopoietic lineage as revealed by 
CD11b+/CD45+, Gr-1+/CD45+, Ter119+, CD41+/CD61+, (B220, CD19)+/CD45+, and 





Figure 36. Whole mouse spleens from lethally irradiated C57BL/6 mice at 14 days post-transplant. A) 
Representative spleen from a mouse IV injected with 5x106 27d.p.i. SLHR-Dsred-MEF suspension cells; B) 
Representative spleen from a mouse IV injected with 5x106 34d.p.i. SLHR-Dsred-MEF suspension cells; C) 
Representative spleen from a mouse IV injected with 5x106 41d.p.i. SLHR-Dsred-MEF suspension cells; D) 
Representative spleen from a control mouse IV injected with vehicle (IMDM) only. All spleens were unfixed at time of 
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Figure 37. FACs analysis of 14-day post-transplant peripheral blood and bone marrow from 27d.p.i. SLHR-
Dsred-MEF suspension cells. 6 mice IV injected with 5x106 suspension cells from 27d.p.i. SLHR-Dsred-MEF, 1 
control mouse IV injected with vehicle only. A) Total Dsred percentage found in PB of 6 mice ranging from 0.3-4.3%, 
and 1 control mouse; B) Left-side: Mature lineage staining of Dsred+ cells from 6 experimental mice injected with 
cells, gated on Dsred+ population showing 2/6 mice with only myeloid lineage contribution, B-cell contribution in 4/6 
mice, and T-cell contribution in 2/6 mice; Right-side: Mature lineage staining of control mouse; C) Total Dsred 
percentage found in BM from 6 mice ranging from 4.5-27%, and 1 control mouse; CD11b+ (macrophage), Gr-1+ 








































































Figure 38. Representative FACs dot plot analysis of 14-day post-transplant peripheral blood from 27d.p.i. 
SLHR-Dsred-MEF. A) Control mouse IV injected with vehicle (IMDM) only, showing 0% Dsred+ cells; B) Mouse 
IV injected with 5x106 27d.p.i. SLHR-Dsred-MEF suspension cells; top plot: unstained peripheral blood sample 
showing 4.3% Dsred+ population; bottom row: same peripheral blood sample stained with mature lineage markers 
showing co-positive populations of Dsred+/CD11b+ (macrophage), Dsred+/Gr-1+ (granulocytes), and Dsred+/(B220, 







Figure 39. FACs analysis of 14-day post-transplant peripheral blood and bone marrow from 34d.p.i. SLHR-
Dsred-MEF suspension cells. 4 mice IV injected with 5x106 suspension cells from 34d.p.i. SLHR-Dsred-MEF, 2 
control mouse IV injected with vehicle only. A) Total Dsred percentage found in PB of 4 mice ranging from 1.6-2.3%, 
and 2 control mouse showing 0% Dsred+; B) Left-side: Mature lineage staining of Dsred+ cells from 4 experimental 
mice injected with cells, gated on Dsred+ population showing both myeloid and lymphoid contribution in 4/4 mice; 
Right-side: Mature lineage staining of 2 control mice; C) Percentage of Dsred+ cells found in BM from 4 mice ranging 
from 0.1-0.8%, and c-Kit+ cells from Dsred+ gated population ranging from 4.5-7.4% from 3 mice, and 2 control mice 
showing 3.5-1.3% c-Kit+ cells in BM; CD11b+/CD45+ (macrophage), Gr-1+/CD45+ (granulocytes), (B220, 


















































































Figure 40. FACs analysis of 14-day post-transplant spleens from 34d.p.i. SLHR-Dsred-MEF suspension cells. 4 
mice IV injected with 5x106 suspension cells from 34d.p.i. SLHR-Dsred-MEF, 2 control mouse IV injected with 
vehicle only. A) Total Dsred percentage found in spleens of 4 mice ranging from 9.2-19%, and 2 control mouse 
showing 0% Dsred+; B) Left-side: Mature lineage staining of Dsred+ cells from 4 experimental mice injected with 
cells, gated on Dsred+ population, showing both myeloid and lymphoid contribution in 4/4 mice; Right-side: Mature 
lineage staining of 2 control mice; CD11b+/CD45+ (macrophage), Gr-1+/CD45+ (granulocytes), (B220, 











































































Figure 41. Representative FACs dot plot analysis of 14-day post-transplant peripheral blood and spleen from 
34d.p.i. SLHR-Dsred-MEF. Mice were IV injected with 5x106 34d.p.i. SLHR-Dsred-MEF suspension cells. A) Single 
cell mature lineage marker staining from peripheral blood; B) Single cell mature lineage marker staining analysis from 
spleen; Note the similarities in staining pattern of donor derived Dsred+ cells with host Dsred- cells; Left plots: Gr-
1+/CD45+ (granulocytes); Middle plots: (B220, CD19)+/CD45+ (B-cells); Right plots: (CD3,4,8)+/CD45+ (T-cells); 








Figure 42. FACs analysis of 14-day post-transplant peripheral blood and bone marrow from 41d.p.i. SLHR-
Dsred-MEF suspension cells. 4 mice IV injected with 5x106 suspension cells from 41d.p.i. SLHR-Dsred-MEF, 2 
control mouse IV injected with vehicle only. A) Total Dsred percentage found in peripheral blood of 4 mice ranging 
from 0.8-2.8%, and 2 control mouse showing 0% Dsred+; B) Left-side: Mature lineage staining of Dsred+ cells from 4 
experimental mice injected with cells, gated on Dsred+ population, showing myeloid and lymphoid contribution in 4/4 
mice; Right-side: Mature lineage staining of 2 control mice; C) Percentage of Dsred+ cells found in BM from 4 mice 
ranging from 0.1-0.8%, and c-Kit+ cells from Dsred+ gated population ranging from 0.4-4.3%, and 2 control mice 
showing 0.2-0.4% c-Kit+ cells in BM; CD11b+/CD45+ (macrophage), Gr-1+/CD45+ (granulocytes), (B220, 
















































































Figure 43. FACs analysis of 14-day post-transplant spleens from 41d.p.i. SLHR-Dsred-MEF suspension cells. 4 
mice IV injected with 5x106 suspension cells from 41d.p.i. SLHR-Dsred-MEF, 2 control mouse IV injected with 
vehicle only. A) Total Dsred percentage found in spleen of 4 mice ranging from 2.3-11%, and 2 control mouse showing 
0% Dsred+; B) Left-side: Mature lineage staining of Dsred+ cells from 4 experimental mice injected with cells, gated 
on Dsred+ population, showing both myeloid and lymphoid lineage contribution in 4/4 mice; Right-side: Mature 
lineage staining of 2 control mice; CD11b+/CD45+ (macrophage), Gr-1+/CD45+ (granulocytes), (B220, 































































Figure 44. Representative FACs dot plot analysis of 14-day post-transplant peripheral blood and spleen from 
41d.p.i. SLHR-Dsred-MEF. Mice were IV injected with 5x106 41d.p.i. SLHR-Dsred-MEF suspension cells. A) Single 
cell mature lineage marker staining from peripheral blood; B) Single cell mature lineage marker staining analysis from 
spleen; Note the similar staining patterns of donor derived Dsred+ cells with host Dsred- cells; Left plots: Gr-
1+/CD45+ (granulocytes); Middle plots: (B220, CD19)+/CD45+ (B-cells); Right plots: (CD3,4,8)+/CD45+ (T-cells); 









Figure 45. In vivo analysis of c-Kit+ population from 27d.p.i. SLHR-Dsred-MEF. A) FACs single cell analysis of 
27d.p.i. SLHR-Dsred-MEF suspension cells. Top plot: unstained control. Middle: histogram of suspension cells 
showing Dsred+ gated population. Bottom plot: c-Kit staining showing 8.8% c-Kit+. Analysis done on FACSAria (BD 
Biosciences); B) Percentage Dsred+ contribution of 14d.p.t. mice IV injected with 5x106 FACS sorted c-Kit+/Dsred+ 
cells from 27d.p.i. SLHR-Dsred-MEF suspension cells. Top chart: total Dsred+ cells detected in peripheral blood (PB) 
and bone marrow (BM). Bottom chart: mature lineage staining of Dsred+ cells found in PB. CD11b+ (macrophage), 
Gr-1+ (granulocytes), (B220, CD19)+ (B-cells), (CD3,4,8)+ (T-cells), Ter119+ (erythrocytes). FACs analysis done on 







Figure 46. FACs analysis of 14 day post-transplant BM, PB, and spleen from 34d.p.i. c-Kit+ SLHR-Dsred-MEF 
suspension cells. 2 mice, IV injected with 1x106 FACS sorted c-Kit+/Dsred+ SLHR-Dsred-MEF suspension cells. A) 
Total Dsred percentage found in BM, PB, and spleens; B) Mature lineage staining of Dsred+ gated cells of PB and 
spleen showing contribution to both myeloid and lymphoid lineages; CD11b+/CD45+ (macrophage), Gr-1+/CD45+ 













































Figure 47. Whole mouse spleens from lethally irradiated C57BL/6 mice at 14 days post-transplant from c-Kit+ 
SLHR-Dsred-MEF suspension cells. A) Representative spleen from a mouse IV injected with 5x106 FACS sorted c-
Kit+/Dsred+ from 27d.p.i. SLHR-Dsred-MEF suspension cells; B) Representative spleen from a mouse IV injected 
with 1x106 FACS sorted c-Kit+/Dsred+ from 34d.p.i. SLHR-Dsred-MEF suspension cells; All spleens were unfixed at 











The ability to successfully reprogram, using a minimal 4-factor combination of 
transcription factors on a WT background, into the hematopoietic lineage was 
impressively confirmed by the results generated utilizing Dsred-MEF. SLHR-Dsred-
MEFs preformed comparably with studies done on p53-/-MEFs in a variety of in vitro 
assays and far surpassed previous in vivo studies. In vivo spleen assays, as well as 
transplantation data, revealed contribution to 3 major hematopoietic tissues up to 3 weeks 
post-transplant. Moreover, contribution was seen in both arms, myeloid and lymphoid, of 
the hematopoietic lineage. Taken together, all assays done on SLHR-Dsred-MEF 
suspension cells, convincingly identify a population of iHPs able to differentiate into both 
mature myeloid and lymphoid hematopoietic cells under in vitro and in vivo conditions.  
As seen in Figure 28, the combination of SLHR was able to produce cobblestone colonies 
in WT MEF, with associated viable suspension cells. Cell surface-marker staining of 
suspension cells identified small populations of mature granulocytes and macrophages, 
but not mature lymphoid cells (Figure 29) as evident by the lack of populations co-
staining for both CD45 and B-cell (B220, CD19) or T-cell (CD3, 4, 8) lineage markers. 
Interestingly, anomalous populations of CD11b+/CD45- and Gr-1+/CD45- were also 
detected (Figure 29B). As CD45 marker expression usually appears before mature 
lineage markers are found (summarized by Hermiston et al. 2002), what exactly these 
populations are is currently under examination. However, the ex vivo skew to myeloid 
identity is most likely due to the imperfect nature of our culture conditions in either 
preserving the HSC or progenitor state, or in providing equal “push” into both the 
myeloid and lymphoid lineages. Not only was single cell staining able to identify mature 
cells, but also revealed a population of progenitors within suspension. According to 
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staining with progenitor marker c-Kit, SLHR-Dsred-MEF suspension cells (Figure 29D) 
contained a progenitor population that was comparable to SLHR-p53-/-MEF suspension 
cells (Figure 21D). Nevertheless surface marker recognition did not provide us with how 
primitive these progenitors were, or the identity of these progenitors. Therefore we 
looked to the CFC assay to evaluate the potential of individual cells.  
The CFC assay allows progenitors to differentiate in line with their potential. Therefore 
conclusions can be drawn about the identity of the progenitor that gave rise to each 
particular colony according to the types of mature cells found within the colony. To that 
end, SLHR-Dsred-MEF suspension cells contained both GMPs as well as their 
committed progenitors, due to the development of CFU-G, CFU-M, and CFU-GM in 
semi-solid culture (Figure 30). The populations of mature granulocytes and macrophages 
found within the starting suspension cell population, identified by surface marker staining 
(Figure 29B), support this conclusion. However, as we did not successfully identify 
colonies comprised of either erythrocytes or megakaryocytes, we could not draw the 
conclusion that the other types of myeloid progenitors were part of the progenitor 
population. As erythroid colonies are a fairly rare occurrence even on the p53-/- 
background, there is a possibility that the co-culture conditions themselves may be 
affecting the WT background in a far more sever way than the knockout background. 
Still this may be a hasty assessment of this progenitor pool as we have only done one trial 
of this assay on these cells. We are, as yet, unsure if this trial is an accurate representation 
of the true progenitor potential found within suspension cells given the unexpected 
success of these cells under biological conditions.  
In vivo studies took one of two paths. As our in vitro assays indicated progenitor 
potential within suspension cells of our culture that were not limited to single lineage-
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committed progenitors; we examine if there was indeed hematopoietic repopulating 
ability of our cells, by utilizing a transplant scenario in which mice were bled every week 
and peripheral blood was assessed for Dsred contribution. Contrary to the approach 
utilized in assessing SLHR-p53-/-MEF, in which we looked strictly for HSC potential, 
SLHR-Dsred-MEF was tested for more restricted progenitors. Thus, contribution was 
assessed at a much earlier time point, beginning at 2 weeks post-transplant, and then 
weekly until 5 weeks post-transplant. By looking before the 4-week mark we were able to 
assess the performance of Dsred cells under biological conditions and gain an idea of 
their ability without assuming the existence of HSC potential. In general, the gradual 
reduction of Dsred contribution to peripheral blood from 2-4 w.p.t. (Figure 33) reinforced 
the idea that our iHPs are not in fact iHSCs. Therefore we chose an assay designed to 
characterize intermediate progenitors in vivo, such as the CFU-S assay.  
Spleen assays have largely been considered the in vivo cousin to the CFC assay, in which 
progenitors are identified by their ability to differentiate into mature lineages. Utilizing 
the ubiquitous expression of Dsred expression by our target cells, we were able to both 
visualize the formation of spleen colonies in host mice, as well as identify the types of 
mature cells being generated within these colonies. As we were hoping to identify the 
most primitive progenitors within suspension, we chose to analyze spleen colonies at 
14d.p.t. Analysis of SLHR-Dsred-MEF total suspension cells exhibited the ability to 
colonize spleens of irradiated mice (Figure 36). Moreover, when colonized spleens were 
assessed for mature lineage identity, contribution to both myeloid and lymphoid lineages 
was found (Figure 40, Figure 43). Staining pattern of donor cells (Figure 41B, Figure 
44B), compellingly, fell well within host cell patterning corroborating the distinctive 
biological nature of SLHR-Dsred-MEF in vivo. Thus, given how these cells preformed in 
the spleen, we had the first indication of the existence of CMP/CLP progenitors.  
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We had concluded the SLHR combination of factors to be the most effective in 
generating iHPs from our studies with p53-/- MEFs. However, those same studies also 
suggested the SLH combination to be comparable. While SLH-p53-/-MEFs were not able 
to continuously generate viable suspension cells for as long as SLHR-p53-/-MEFs, they 
performed analogously in other in vitro assays. Therefore we also tested the SLH 
combination on the WT MEF background using Dsred-MEF. In vitro assay results were 
akin to those seen using SLH-p53-/-MEFs. We also took the opportunity to place them 
through the CFU-S assay to investigate their potential under in vivo conditions. Perhaps 
unsurprisingly, SLH-Dsred-MEF suspension cells were only able to colonize spleens 
when injected at 27d.p.i., albeit with no obvious difference in efficiency. By 34d.p.i., 
however, there was no indication of Dsred+ cells in spleen from mice injected with SLH-
Dsred-MEF. This reaffirmed our conclusion that SLHR was the minimal combination of 
factors to inducing hematopoietic progenitor identity from fibroblasts.  
 
Note that we evaluated spleen colonies later than literature and BM standards, with CFU-
S12 indicative of the most primitive progenitors with the ability to contribute to both 
myeloid and lymphoid lineages, as well as recurrent colonization ability. However, as our 
cells showed obvious delays in differentiation kinetics, as seen in the CFC assay as well, 
assessing them at a later time point was done to allow for complete colony development. 
We also assessed total spleen for mature lineage identity, as the nature of the colonies 
formed in spleen did not allow for dissection of individual colonies for clonal evaluation.  
However, this limitation did prevent us from drawing more definitive conclusions as to 
the types of progenitors generated. Consequently, the existence of Dsred+ lymphoid and 
myeloid mature cells in spleen only tells us that at best, donor cells contained CMPs and 
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CLPs when introduced into the assay. Until we are able to see both mature myeloid and 
lymphoid cells contained within the same spleen colony, we are unable to conclude the 
identity of the MPP. 
As the CFU-S assay requires the sacrifice of mice at 14d.p.t., we took the opportunity to 
also assess two other hematopoietic tissues, peripheral blood and bone marrow, for 
contribution. Within PB donor cells were found to have contributed to both myeloid and 
lymphoid mature cell fractions. There was not a significant difference in donor cell 
contribution ability when 27, 34, or 41d.p.i. was considered (Figure 37A, Figure 39A, 
Figure 42A). Mature lineage contribution of donor cells within PB still showed allocation 
into both myeloid and lymphoid lineages (Figure 37B, Figure 39B, Figure 42B). 
Comparing mature cell ratios of Dsred+ gated cells to control mice did indicate a slight 
skew to granulocytes and monocytes for 27d.p.i. SLHR-Dsred-MEF suspension cells that 
was not apparent in 34 or 41d.p.i. trials. Again, in an effort to convince ourselves of the 
genuineness of donor cell identity, we looked to staining patterns within FACS plots 
(Figure 38, Figure 41A, Figure 44A). The resulting similarities in patterning between 
host and donor cells, within mature lineage marker staining, reaffirm the legitimacy of 
SLHR-Dsred-MEF under biological conditions.  
Bone marrow analysis was less encouraging as it was only 27d.p.i. SLHR-Dsred-MEF 
suspension cells that showed any significant contribution to this niche (Figure 37C). 34 
and 41d.p.i. was unable to show a population of Dsred+ cells greater than 1% (Figure 
39C, Figure 42C), whereas 27d.p.i. suspension cells showed a range of 4.4-27.1%. This 
vast difference in engraftment, together with PB performance, indicated the possibility of 
two distinct populations between 27d.p.i. and the later 34 and 41d.p.i. cultures. This 
hypothesis needs further investigation before a conclusion can be arrived at, as results 
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generated from CFU-S from 27d.p.i. suspension cells were not as complete as for the 
other time points. Be that as it may, as BM did not show significant engraftment only 
bolsters the idea of a lack of iHSC in suspension, as intermediate progenitors would not 
be as successful in engrafting into the BM niche (Nilsson et al. 2001; Celso et al. 2008; 
Lam and Adams 2010).  
Lastly, as we had seen a substantial faction of c-Kit+ cells within SLHR-Dsred-MEF 
suspension cells (Figure 45A), we looked to see if this fraction would have an enhanced 
ability to colonize spleen, contribute to PB, or engraft within BM. c-Kit enrichment of 
cells when injected at the same amount as total suspension cells yielded spleens that were 
larger, and contained more Dsred+ colonies (Figure 47A), than total suspension cells 
(Figure 36A). This trend was also seen when PB contribution was examined, where c-Kit 
enrichment resulted in about a 10-fold increase of Dsred contribution (Figure 45B), 
compared to total suspension cells (Figure 37A). However, mature lineage staining of the 
Dsred+ fraction (Figure 45B) did not demonstrate any significant differences in the 
lineage ratios seen in mice injected with total suspension cells (Figure 37B). When BM 
was examined of c-Kit+ enriched suspension cells (Figure 45B), donor contribution was 
comparable to total SLHR-Dsred-MEF suspension cells (Figure 37C). In fact, when the 
amount of c-Kit enriched suspension cells injected (1x106) was dropped to one-fifth the 
amount of total suspension cells injected (5x106), spleen colony formation (Figure 47B, 
Figure 36B), and subsequent percent contribution (Figure 46, Figure 40A), was still 
comparable. PB contribution also showed comparable Dsred+ populations (Figure 46A) 
when compared to injections of total suspension cells (Figure 39A), as did examination of 
BM. Again, mature lineage staining failed to display obvious differences in mature cell 
ratios in either PB or spleen (Figure 46B), confirming c-Kit as a pan-progenitor marker. 
Overall, c-Kit enrichment of suspension cells did enrich for progenitors, given the 
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augmented contributions seen in spleen, PB, and BM, when 5x106 cells were injected; 
and the comparable performance seen when only 1x106 cells were injected.  
On the whole, our experiments with Dsred-MEF proved the power of the minimal SLHR 
combination of factors in creating iHP able to perform under both in vitro assays as well 
as in vivo assays. In vitro examination revealed the existence of bi-potential myeloid 
progenitors in suspension capable of generating CFU-GM colonies in CFC assays. This is 
supported by the limited differentiation of granulocytes and monocytes found in 
suspension. The inability to recognize lymphoid identity in vitro mirrors previous results 
from p53-/-MEF, and is likely due to culture conditions under which cells were cultured ( 
(Ehrlich et al. 2011). In vitro findings point to successful generation of iHP of the 
myeloid persuasion. In vivo assays however, revealed lymphoid potential not seen in ex 
vivo culture. Extensive studies of 14d.p.t. mice, injected with both total and c-Kit 
enriched suspension cells, expose the limited ability of these cells to repopulate the 
murine hematopoietic system. Progenitor potential shown in CFC assay was confirmed 
under biological conditions in the CFU-S assay. In fact, spleen colonies and PB, 
demonstrated the existence of lymphoid progenitors, exposed by mature lineage staining. 
However, as yet it is still unknown if the progenitors giving rise to myeloid and lymphoid 
mature cells in PB and spleen were due to bi-potential GMPs, MEPs, CMPs, and CLPs, 
or due to the more primitive MPP, as individual colonies have yet to be assessed for 
composition. Despite some unknown details, it is clear SLHR is able to reprogram WT 


















A progressive approach to reprogramming fibroblasts into hematopoietic progenitors was 
traversed over the course of this thesis. It involved 3 different genetic backgrounds; and a 
methodical evolution from the use of 6 transcription factors, and two powerful 
oncogenes, to a combination of 4 crucial factors, to prove the successful creation of iHPs, 
of both myeloid and lymphoid identity. An array of assays spanning in vitro and in vivo 
conditions were used to confirm the entrance into the hematopoietic lineage.  
We first overexpressed 6 transcription factors deemed important in generating and 
sustaining the HSC, and 2 oncogenes (MT) to drive cell cycling in the hematopoietic 
reporter line Runx1-GFP-MEF. We were able to show, that the hematopoietic identity 
could be achieved from a cell as dissimilar as the fibroblast through production of viable 
suspension cells, recognized by erythrocytic and megakaryocytic mature lineage markers. 
Furthermore these cells demonstrated progenitor ability as seen by the outgrowth of 
benzidine- and acetylcholinesterase-positive colonies when placed into the CFC assay. 
The success of this experiment fortified the idea of attainable iHPs given the correct 
approach.  
We modified the method of deriving iHPs as the overexpression of c-Myc (M) was 
perturbing the normal differentiation of myeloid progenitors. However, it was crucial to 
preserve the increased cell cycling effect achieved thorough MT overexpression. 
Therefore, we looked to p53-/-MEFs as targets in reprogramming, as this would allow us 
to sustain a higher rate of cellular turnover, without sacrificing potential differentiation 
abilities. We also sought ex vivo conditions better suited to maintaining hematopoietic 
progenitors. Thus we continued with an appropriate feeder layer and media supplemented 
with hematopoietic cytokines, and removed the use of MT. The resulting 6F-p53-/-MEFs 
generated suspension cells with the ability to produce granulocytes, monocytes, and 
! ! !!150!
erythrocytes, in semi-solid media as well as liquid culture. Moreover, these cells showed 
limited contribution to peripheral blood in NSG mice when assayed at 4w.p.t., indicative 
of progenitor potential in both in vitro and in vivo conditions. We concluded then that we 
had managed to create iHPs with multilineage erytho-myeloid potential in 6F-p53-/-MEF.  
Success seen with a pool of 6 hematopoietic TFs subsequently led to the search for the 
minimum factors crucial to the generation of iHPs. Factor screening, done in p53-/-MEFs, 
identified a 4-factor combination (SLHR), which was able to generate iHPs as identified 
by c-Kit expression and in vitro differentiation assay. SLHR-p53-/-MEF generated the 
most cobblestone colonies as well as viable suspension cells. Suspension cells from this 
combination also produced c-Kit+ cells. When placed in the CFC assay, the SLHR 
combination produced the most erythroid and myeloid colonies exhibiting normal nuclear 
morphology. Therefore we identified this 4-factor combination as the most suitable to 
assess on a wild-type genetic background. As the p53-/- cell line is essentially a cancer 
cell line, it was imperative to evaluate our method on a non-modified genetic 
background.  
We selected Dsred-MEF as target cells for two main reasons. These cells were 
genetically normal, yet were able to constantly produce red fluorescence in a ubiquitous 
manner. This fluorescence facilitated tracking the performance of these cells under in 
vivo conditions. There was however a slight decrease in the efficiency of SLHR-Dsred-
MEFs, as determined by cobblestone colony count and CFC count. This was not 
surprising, as the cells had lost the increased cell cycling characteristic of the p53-/- 
background. In vitro CFC assay also failed to identify erythroid progenitors in the SLHR-
Dsred-MEF suspension cells. Nevertheless, no real difference was found in c-Kit+ 
populations in liquid culture between the knockout and WT background. In general, in 
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vitro results corroborated the results seen in SLHR-p53-/-MEF, with the generation of 
iHPs showing at least MEP and GMP activity, and without indication of lymphoid 
activity. This skew toward the myeloid seems to be due to the ex vivo culture conditions 
themselves, as the cytokines used to culture and assay these cells are better known for 
their interaction with the myeloid progenitors than the lymphoid arm (Eto et al. 2002; 
Miller and Eaves 1997; Nakano et al. 1996; Ehrlich et al. 2011; Haylock et al. 1992; 
Pereira et al. 2007; McNiece et al. 1989). In vivo results, moreover, also highlight the 
lingering insufficiencies in successfully culturing hematopoietic progenitors and HSCs 
without spontaneous differentiation.  
In an effort to examine the performance of SLHR-Dsred-MEF under biological condition, 
we injected cells into C57BL/6 mice. As we had previously failed to see robust 
contribution to PB at 4w.p.i., the earliest indication of HSC activity (Yang et al. 2005), 
we tracked donor cell contribution in PB before 4w.p.i. We found populations of donor 
cells with mature hematopoietic identity, showing a potential similar to restricted 
progenitors, but not HSCs (Nakorn et al. 2002; Yang et al. 2005). Therefore looking for 
spleen colonies emerged as the more appropriate in vivo assay for these SLHR-Dsred-
MEF iHPs. Data indicated lymphoid potential not previously seen in ex vivo culture. 
Results from the CFU-S assay revealed robust colonies at 14d.p.t., akin to CFU-S12 
derived from CMP and CLPs (Nakorn et al. 2002). 
While we can definitively conclude that they are progenitors with myeloid and lymphoid 
potential within the suspension cell population, we cannot as yet draw a conclusion to 
their specific identity, as we did not examine the makeup of individual spleen colonies. 
Moreover, we cannot determine if it is a pool differently committed progenitors, or if 
there exists more primitive progenitors of multiple lineage potential, such as the MPP. 
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Nevertheless, further study into the composition of individual spleen colonies will allow 
us to examine the potential of individual progenitors in a clonal fashion, allowing us to 
definitively classify the kinds of iHPs being generated.  
As we utilized a constitutive promoter to overexpress our TFs, studies to determine if 
these factors are still being expressed in our iHPs are ongoing. It is important to establish 
both the successful integration and methylation status of our TF genes, as this provides 
insight to the stability of the reprogramed identity.  
Over the course of this thesis we have shown the ability to transform the identity of 
fibroblast cells into hematopoietic lineage progenitors. Use of highly proliferative p53-/-
MEF allowed the identification of TFs crucial to the generation of iHPs, without 
perturbing the normal differentiation potential by overexpression of c-Myc. Confirmation 
of successful hematopoietic progenitor induction on a WT genetic background validated 
the results seen in p53-/-MEFs, and certified the authenticity of iHPs. Assessment of iHPs 
under both in vitro and in vivo conditions proved normal myelo-lymphoid differentiation 
capacity in culture as well as under stricter biological conditions. There is more to be 
done to definitively identify the specific progenitors being induced, as well as to 
determine culture conditions able to capture iHSC, and promote proliferation without 
allowing differentiation. Nevertheless, we have achieved the successful generation of iHP 
from MEF through overexpression of 4 TFs essential to the generation and maintenance 
of HSCs.  
The finding reported in this thesis have thus highlighted the malleability of cellular 
identity, manipulation of which may allow us to eventually target specific tissue systems 
with greater efficiency than current technology. In the context of human life, the need for 
blood is ever present, be it to maintain homeostasis, or survival from a surgery or trauma. 
! ! !!153!
This dynamic system is the easiest organ to donate and transplant in its mature form, and 
when done correctly, poses little risk to both donor and recipient. Yet, we face a chronic 
shortage daily, worldwide. Our work, while in its infancy, takes the first steps to 
addressing this blood shortage, from mature to HSC transplants in leukemic treatments, 
by exploring the feasibility of generating the hematopoietic lineage through cellular 
reprogramming. Others have and still are investigating the directed manufacture of blood 
from pluripotent stem cells, while yet more groups scrutinize for a way to proliferate 
HSCs from primary sources. Through the many forms, we all work towards the same 
goal, made to order blood. Ultimately the idea of personalized medicine can be achieved; 
with both ES differentiation as well as somatic cell reprogramming, the options should be 
endless.  
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